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Fibrosis represents a major global disease burden, yet a potent antifibrotic 
compound is still not in sight. Part of the explanation for this situation is the 
difficulties that both academic laboratories and R&D departments in the 
pharmaceutical industry have been facing in re-enacting the fibrotic process in 
vitro for screening procedures prior to animal testing. Effective in vitro 
characterization of antifibrotic compounds has been hampered by cell culture 
settings that are lacking crucial cofactors or are not holistic representations of 
the biosynthetic and depositional pathway leading to the formation of an 
insoluble pericellular collagen matrix. Only when collagen has formed a 
fibrillar matrix that becomes cross-linked, invested with ligands, and can be 
remodeled and resorbed, the complete picture of fibrogenesis can be reflected 
in vitro. We developed the Scar-in-a-Jar, which implements for the first time in 
vitro the complete biosynthetic cascade of collagen matrix formation including 
complete conversion of procollagen by collagen C-proteinase/BMP-1, its 
subsequent extracellular deposition and lysyl oxidase-mediated cross-linking. 
This is achieved by applying the biophysical principle of macromolecular 
crowding. Collagen matrix deposition velocity and morphology can be 
controlled using negatively charged crowders in a rapid (2 days) mode and a 
mixture of neutral crowders in a novel accelerated (6 days) mode. Combined 
together with quantitative optical bioimaging, this novel system allows for in 
situ assessment of the area of deposited collagen(s)/cell. A well thought-out in 
vitro fibrogenesis system represents the missing link between brute force 
 vi 
chemical library screens and rational animal experimentation, thus providing 
both cost-effectiveness and streamlined procedures towards the development 
of better antifibrotic drugs.  
 
Only upon identification of effective compounds will we then be able to 
address the current bottleneck in tissue engineering, peri-implantational 
fibrosis, which not only impede the implants original remedial purpose, but 
also exacerbates the problem. Compounds from the prolyl-4-hydroxylase 
inhibitor (PHi) substance class were shown to have antifibrotic potential by the 
Scar-in-a-Jar, and are further known to stimulate angiogenesis. We believe 
that local delivery of 2,4-pyridinedicarboxylic acid (PDCA), ciclopirox olamine 
(CPX) and hydralazine (HDZ) via a material will elicit both antifibrotic and 
angiogenic tissue behaviour. Besides delivering drugs, some design 
considerations of such a material include its ability to support cell attachment, 
proliferation and infiltration, which was attained by our composite material 
comprising coelectrospun micron-sized medical grade poly(-
caprolactone)/collagen (mPCL/Col) with codeposited HeprasilTM, a hyaluronic 
acid hydrogel containing heparin. mPCL/Col-Hep was used to deliver PHi in 
two modes, via HeprasilTM (mode 1), or the microfibers (mode 2). Mode 1 was 
tested in a rat renal pouch model and fibrosis was not apparent around the 
implanted materials within 7 days, even in controls without PHi. 
Concentrations of 10 mM PDCA and 10 μM HDZ showed blood vessel 
infiltration comparable to VEGF delivery, and at this point, served as a proof-
of-concept that local delivery of PHi can aid angiogenesis.  
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This chapter introduces the hypotheses driving this project and their 
substantiations. The three aims and their objectives are highlighted and the 
research methodologies to accomplish these aims are briefly described. 
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1.1 Background 
Fibrosis, a pathological accumulation of collagen in tissues, represents a 
major global disease burden. In the field of tissue engineering, peri-
implantational fibrosis is a bottleneck that often leads to implant failure. In 
order to address this issue, identification of potential antifibrotic compounds is 
essential and represents the first step towards the development of antifibrotic 
biomaterials for use in tissue engineering. Unfortunately, effective 
characterization of antifibrotic lead compounds has been constrained by poor 
extracellular matrix formation in vitro, and the inability to normalize matrix 
content for cell numbers in the same well.  
 
The hypotheses behind this research project is that: 
1. Development of an effective scar-in-a-jar in vitro screening tool 
will enable identification of antifibrotic compounds  
2. Local delivery of prolyl hydroxylase inhibitors will elicit both 
antifibrotic and angiogenic tissue behaviour around an implant  
 
 
These hypotheses are based on the following observations: 
 
a) Fibrogenic cells in monolayer culture do not lay down significant amounts 
of collagen in a useful time window for screening [1, 2].  
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b) The amount of deposited extracellular matrix (ECM) in relation to the 
number of cells in the same culture well currently requires the destruction 
of cell layers to obtain protein or DNA [3-5].  
 
c) Current quantitation methods are either not specific, have low sensitivity, 
require prior solubilization of deposited collagen for quantitation, or are too 
slow for use as a screening tool [6].  
 
d) The main problem faced by a biomaterial is the formation of an avascular 
collagen capsule surrounding the implant, causing implantable devices 
and materials to lose functionality over time [7]. 
  
e) Hypoxia and fibrosis progression occur simultaneously [8], and the 
absence of vasculature to distribute oxygen and other nutrients within a 
tissue-engineered device is a major limiting factor [9]. 
 
f) Prolyl hydroxylase inhibitors possess antifibrotic and angiogenic potential 
[10, 11]. 
 
Based on these observations, the experimental focus of this project is on 
1. the development of a fully functioning scar-in-a-jar to enable the 
identification and hence comprehensive in vitro verification of 
novel antifibrotic compounds, and 
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2. the design considerations of a material to deliver PHi to prevent 
fibrosis, but support cell attachment, proliferation and blood 
vessel infiltration.  
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1.2 Aims and Objectives 
 
In order to provide a thorough assessment of the hypothesis and achievement 
of an antifibrotic biomaterial to reduce peri-implantational fibrosis, this 
research project was divided into three specific aims: 
 
Specific aim #1: Establishment of an automated microscopy-based in situ 
ECM assessment system with complete collagen deposition in vitro 
A microscope capable of automated immunofluorescent image acquisition will 
be optimized to cover the maximum possible area in a multi-well plate format. 
Morphometry software will be utilized to measure ECM signals and count 
nuclei, thereby superseding extraction of DNA and associated assays. ECM 
proteins other than collagen will be included in order to confirm the specificity 
of inhibitor action on collagen biosynthesis and not a general reduction of 
protein production. Cytoskeletal elements such as  smooth muscle actin (-
SMA), which is indicative of myofibroblast activation and one of the hallmarks 
of fibrosis can be quantified as well. Macromolecular crowding was used to 
enhance collagen deposition in vitro, and two modes were developed for 
different purposes. 
 
Specific aim #2: Screening of substances targeting key points of collagen 
biosynthesis to assess their antifibrotic potential  
Substances recognized for their antifibrotic action targeting various points of 
collagen biosynthesis and turnover were used to ascertain the Scar-in-the-
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Jars capability of detecting variations in collagen deposition. A collaboration 
with Pfizer provided novel C-proteinase inhibitors for testing. The use of 
miRNA prediction software such as rna22 and TargetScan aided in 
determining miRNAs that target the genes of key players in the collagen 
biosynthetic pathway, as well as those responsible for fibrosis. 
 
Specific aim #3: Development of an antifibrotic and self-vascularizing material  
Compounds identified by the Scar-in-a-Jar to have antifibrotic properties were 
incorporated into a biomaterial in order to prevent peri-implantational fibrosis. 
Substances from the class of compounds, prolyl-4-hydroxylase inhibitors 
(PHi), were shown to have antifibrotic potential, and are known to stimulate 
angiogenesis. As a proof-of-concept, a material comprising coelectrospun 
micron-sized medical grade poly(-caprolactone)/collagen (mPCL/Col) with 
codeposition of HeprasilTM, a hyaluronic acid hydrogel, was used to deliver 
PHi in two modes, via either the hydrogel component (mode 1), or the 
microfibers (mode 2). In vitro and in vivo assessment of antifibrotic and 
angiogenic properties were performed.  
 
 7 
1.3 Research Methodology 
 
1.3.1 Specific aim #1: Establishment of an automated microscopy-based 
in situ ECM assessment system with complete collagen deposition in 
vitro  
The bioimaging aspect of this approach is based on a: 
• Fully motorised inverted microscope (X/Y stage, autofocus (Z-axis), 
filterwheel)  
• High sensitivity monochromatic CCD camera cooled down to – 30oC 
• Complex imaging software to control hardware movements, data 
capturing, image calculation, image merging and quantitation of signals 
 
We aim to quantify relative fluorescence intensities from immunolabelled 
extracellular matrix with the system configuration proposed. The filter systems 
allow for the discrimination of up to six excitation/emission wavelengths which 
have been chosen because they correspond to international industrial 
standard throughput systems. The available excitation wavelengths can be 
used to retrieve signals for up to six different fluorochromes. In turn, they are 
used in one and the same cell culture well to image and quantify (1) cell 
numbers using nuclear stain such as DAPI (2) amount of a deposited collagen 
type (3) amount of a deposited non-collagenous ECM protein (e.g. 
fibronectin), (4) separate assessment of intracellular collagen or another 




Collagen deposition in vitro was enhanced with the use of macromolecular 
crowding in culture with known [2] and new macromolecules [10], in order to 
obtain a complete cascade of collagen biosynthesis for a thorough 
assessment of antifibrotic compounds. We compared our system with the 
fibroplasia model [12], which consists of TGF-exposed hyperconfluent 
fibroblasts that form cell sheets. These need to be removed for histology and 
total protein hydrolysis to assess the hydroxyproline content without the option 
to correct for cell number or total protein content. A modified version has been 
used by a Pfizer team to assess C-proteinase inhibitors [13].  
 
We intend to develop an in situ assessment system for antifibrotic compounds 
to obtain results within a shorter time frame. 
 
1.3.2 Specific aim #2: Screening of substances targeting key points of 
collagen biosynthesis to assess their antifibrotic potential  
The overall objective of these experiments was to confirm that the Scar-in-a-
Jar is capable of detecting perturbations at any target keypoint of collagen 
biosynthesis. Therefore, only one assay system will be required regardless of 
the inhibitors target.  Any effects on cell proliferation caused by the inhibitor 
will also be accounted for by the Scar-in-a-Jar, allowing for accurate 
assessment of collagen biosynthesis interference.  A range of antifibrotic 
substances was selected based on their ability to inhibit collagen 
production/deposition at different points of the collagen biosynthesis pathway 
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(Table 1). The effects of these substances were subjected to parallel optical 
and biochemical analyses for verification of the screening capabilities of the 
Scar-in-a-Jar. 
 
We had recently predicted microRNA 29c to target procollagen 1(I) mRNA by 
the rna22 algorithm [14].  The ability of mimic and inhibitor miR29c molecules 
to affect collagen I deposition was assessed by the Scar-in-a-Jar. This is first 
evidence at the protein level for a potential antifibrotic effect of mimic miR29c 
and demonstrates the advantage of a read-out system reporting the net 
reduction of collagen I, regardless of multiple targets being affected 
simultaneously. 
 
Procollagen cleavage by procollagen C-proteinase (PCP) was demonstrated 
to be enhanced under macromolecular crowding in vitro [10]. This feature of 
the Scar-in-a-Jar allowed for assessment of C-proteinase inhibitors under 
native enzyme/substrate conditions, which was not possible prior to this set-
up.  A novel sulfonamide PCP inhibitor (PCP56) from Pfizer and another 
inhibitor (FSY002) from Fibrosys (originally from Bayer AG) were tested for 
their effects on collagen I deposition by the Scar-in-a-Jar.   
 
1.3.3 Specific aim #3: Development of an antifibrotic and self-
vascularizing material—design considerations 
As a proof-of-concept, prolyl hydroxylase inhibitors were selected for 
incorporation into a material. Specifically, 2,4-pyridinedicarboxylic acid 
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(PDCA), ciclopirox olamine (CPX) and hydralazine (HDZ) were used. These 
substances activate the angiogenic pathway via stabilization of hypoxia-
induced factor-1 (HIF-1), as well as reduce collagen I secretion by inhibiting 
prolyl-4-hydroxylase, thus resulting in destabilized procollagen triple helices.  
 
Table 1 Known/novel antifibrotic compounds and their target synthetic keypoints 
 
A composite biomaterial comprising electrospun poly(-caprolactone)/collagen 
microfibers with a codeposited hyaluronic acid hydrogel containing heparin 
(HeprasilTM) was used to deliver PHi via the hydrogel (mode 1) or the 
microfibers (mode 2). Its ability to support cell attachment, proliferation and 
infiltration were assessed in vitro. The angiogenic and antifibrotic potential of 
this material was investigated in vitro via ELISA for VEGF production, 
quantitation of collagen I and capillary-like structure formation of endothelial 
cells in endothelial-fibroblast co-cultures. A rat renal pouch model was used to 








Focus on collagen: in vitro systems to study 











This chapter highlights the problem of fibrosis and describes its progression 
and the complexities involved.  A summary of challenges faced by current 
methods commonly used to quantify collagen in vitro is presented and this 
emphasizes the urgent need to develop a better screening system to identify 
potential antifibrotics. 
 
This chapter of the thesis has been adapted from the candidates published 
review:  
Chen CZC and Raghunath M. Focus on collagen: in vitro systems to study 




2.1 Fibrosis—ubiquitous problem and global burden 
 
Repair of damaged tissues is an essential biological process to allow directed 
replacement of dead or damaged cells with connective tissue after injury. The 
repaired area is addressed as a scar. Hence, scarring represents a survival 
mechanism that is conserved throughout evolution, and appears to be most 
pronounced in humans. If this wound healing process goes awry, fibrosis 
results in an excessively large scar or the scarry transformation of organ parts 
or whole organs. Besides local scarring at sites of acute trauma, a variety of 
other causes such as chronic infections, chronic exposure to alcohol and 
other toxins, autoimmune and allergic reactions, radio- and chemotherapy can 
all lead to fibrosis. This pathological process therefore can occur in almost 
any organ or tissue of the body, and typically results from situations persisting 
for several weeks or months in which inflammation, tissue destruction and 
repair occur simultaneously. In this setting, fibrosis most frequently affects the 
lungs, liver, skin and kidneys. There are approximately 5 million cases of 
idiopathic lung fibrosis globally [15], not counting rare disorders like cystic 
fibrosis or very common ones like asthma. Chronic hepatitis virus B and C are 
a major cause of liver fibrosis/cirrhosis which currently ranks 18th of the global 
disease burden [16]. Scar formation after myocardial infarction can on one 
hand prevent the injured myocardium from dilatation and rupture, but on the 
other hand, it can impair cardiac function through increasing ventricular wall 
stiffness [17]. Atherosclerotic lesions contain fibrotic tissue which can occupy 
up 87% of total plaque area [18].  
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Peri-implantational fibrosis represents a current clinical roadblock in 
regenerative medicine, which is gaining attention in the tissue engineering 
field. Every implant is surrounded by a fibrotic tissue reaction that depends on 
the material, its surface and its degradation profile [7, 19, 20].  This is a 
consequence of chronic local inflammation and a reflection of the hosts tissue 
attempt to destroy the implant or to cope with it. If destruction is not an option, 
the implants get wrapped in a fibrous shroud with sparse or no 
vascularization, so that it becomes effectively isolated from the surrounding 
tissue. This is seen in artificial ligaments [21, 22], implanted biosensors [23, 
24], joint implants [25, 26], breast implants [27, 28], encapsulated tissues/cells 
[29, 30], drug delivery systems [31] and eye implants [32, 33], and regularly 
impairs the proper function of the implant. This has prompted the field to alter 
surface structures and coatings to contain this problem [3, 4, 7, 34-38]. A 
potential strategy could be to develop biomaterials that will deliver an 
antifibrotic substance locally [11, 28, 39].  
 
It becomes clear that the development of effective antifibrotics is an important 
unmet clinical need, and with it remains the necessity for rapid in vitro 
screening tools to characterise lead antifibrotic compounds before they are 
tested in animal models. This review will focus on the current state of the art 
to emulate a fibrotic process in vitro, the associated challenges and pitfalls 




2.2 Fibrogenesis in vivo—complexity and key players 
 
In order to appreciate the task which in vitro screening of antifibrotics is up 
against we shall dissect the fibrotic process into two categories, firstly, events 
that are upstream of collagen biosynthesis and secondly, the biosynthetic and 
depositional cascade of collagen I.  
 
2.2.1 Upstream events of fibrosis—cellular players in vivo 
 
Trauma disrupts the anatomical cohesion of tissue structures, most evident by 
bleeding which indicates breakage of blood vessels and disruption of their 
endothelial lining. This immediately induces a haemostatic response 
encompassing platelet aggregation, blood clot formation, and accumulation of 
provisional ECM [40]. Damaged epithelia secrete cytokines, growth factors 
and chemoattractants for mononuclear cells to phagocytose cellular debris at 
the site of injury and for fibroblasts to deposit collagen and remodel it. Thus, a 
scar is formed that eventually matures. The origin of these fibroblasts is 
currently a matter of debate. They are either differentiating homing 
mesenchymal stem cells [41], fibrocytes from the blood circulation [42], or are 
derived from epithelia via epithelial–mesenchymal transition (EMT) [43]. The 
fibroblasts involved in scarring have a myofibroblast phenotype characterised 
by -smooth muscle actin (-SMA) expression, increased secretion of 
collagen type I and III, and contractility [40]. These cells are believed to be 
responsible for the majority of collagen production in most organs. 
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2.2.2 “Soluble” factors mediating fibrosis 
 
The cellular effectors of fibrosis are activated, and phenotypically modulated 
by humoral players, namely chemokines, growth factors and cytokines. Most 
notorious is transforming growth factor 1 (TGF-1) which supports wound 
healing and repair. Under pathological conditions, TGF-1 coordinates a 
cross-talk between parenchymal inflammatory and collagen-expressing cells, 
and plays a key role in fibrosis progression. TGF-1 is often referred to as a 
“soluble” factor. We use quotation marks here because TGF-1 is stored in its 
latent form bound to TGF-1 binding proteins in the matrix [44], and can in its 
active form be scavenged and possibly neutralized  by decorin-mediated 
binding into the ECM [45, 46] (for review see [47]). 
 
Along with factors like epithelial growth factor, basic fibroblast growth factor 
and interleukin-1, TGF-1 appears to play a key role in EMT [42].  The 
connective tissue growth factor [48] and platelet-derived growth factor [49] 
have also been reported to be involved in fibrosis (for a more in-depth review 
on cytokines and molecular mechanisms involved in fibrogenesis, refer to 
[50]). Inflammation typically precedes fibrosis, although it has been 
demonstrated that fibrosis is not necessarily driven by inflammation at all 
times. This suggests that the mechanisms that regulate fibrogenesis are to a 
certain extent distinct from those regulating inflammation [51]. This may 
explain the lack of efficacy of anti-inflammatory compounds in the treatment of 
fibrotic disease [52]. Antifibrotic strategies at the upstream level aim to 
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interfere with fibrotic growth factors and make use of interfering antibodies 
[53-56], small molecules [13, 49], proteins [57, 58], antisense technology [59, 
60] or the use of human recombinant TGF-3. TGF-3 is an alleged TGF-1 
antagonist, that has shown some promise in phase III clinical trials in a 
prophylactic setting of small skin wounds [61].  
 
2.3 Understanding the last mile of the fibrotic pathway 
 
Irrespective of upstream events that trigger and entertain fibrosis, the final 
product of cellular activity is the massive deposition of collagen resulting in 
scar formation, organ or peri-implantational fibrosis. We therefore would like 
to turn now to the obvious target in fibrosis, namely the biosynthetic pathway 
of collagen itself.  
 
The overall amount of collagen deposited by fibroblasts is a regulated balance 
between collagen synthesis and collagen catabolism, which is a carefully 
controlled process. During a pathological maturation and remodeling phase, 
collagen synthesized by fibroblasts exceeds the rate at which it is degraded 
such that the net amount of collagen continues to increase. There are several 
keypoints along the collagen biosynthesis pathway that can be targeted to 
effect a net reduction of collagen secretion and/or deposition (Figure 1). 
Transcription interference can be affected using histone deacetylase inhibitors 
[62, 63] or substances like halofuginone [64, 65]. At the post-transcriptional 
level, siRNA targeting growth factors and keyplayers have been investigated 
[59, 60, 66], and recently, we and others have suggested the use of 
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microRNAs [67, 68]. Interfering with post-translational modifications by 
inhibiting prolyl-4 hydroxylase renders collagen triple helices less 
thermostable and prevents their secretion [68, 69], down-regulation of 
collagen chaperone hsp47 does likewise [70, 71]. At the extracellular level, 
inhibition of procollagen C-proteinase/BMP1 prevents the removal of the C-
terminal propeptide from the procollagen I molecule and thus the 
supramolecular assembly of collagen into fibrils [13, 68]. Inhibition of lysyl 
oxidase mediation of inter-molecular cross-links between collagen triple 
helices can reduce collagen content of the ECM, presumably by rendering 
collagen aggregates more susceptible to proteolytic remodelling [12]. 
Similarly, the administration of hepatocyte growth factor [72] and matrix 
metalloproteinase 1 (MMP1) [57, 58] increases collagen turnover in the ECM. 
It becomes clear that a meaningful in vitro system for the testing and 
characterisation of antifibrotics should be able to emulate the above described 
complete collagen matrix formation cascade, encompassing its biosynthesis 
and all post-translational (intra- and extra-cellular) modifications that give rise 
to a stable supramolecular assembly, and also ideally allow the study of 
remodelling/fibrolysis. For the sake of convenience and efficiency for 
screening purposes, quantitation of collagen and other proteins of interest 




Figure 1 Potential points of interference along the collagen biosynthesis 
pathway.  1) Epigenetic level: HDAC inhibitors. 2) Post-transcriptional level: mRNA 
translation is reduced by miRNAs/siRNAs. 3) Post-translational level: prolyl-4-
hydroxylase inhibitors reduce the stability of the procollagen triple helix. 4) 
Reduction/inhibition of the collagen chaperone hsp47 (   ) also reduces stability of the 
procollagen triple helices, resulting in intracellular retention and degradation. 5) Post-
secretional level: Inhibition of procollagen proteinases (    )  prevents deposition of 
insoluble collagen molecules on the cell layer. 6) Collagen crosslinking: Inhibition of 
lysyl oxidase (LOX) hypothetically renders the collagen more susceptible to 
degradation. 7) An increase of MMP1 (     ) results in faster collagen degradation and 
turnover. Figure from [6] 
 
2.4 Fibrogenesis in vitro—constraints and options 
 
The task of emulating collagen matrix formation in vitro has been surprisingly 
difficult, partly due to the omission of important cofactors, and partially 
because of intrinsic properties of contemporary cell culture conditions that still 
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are largely unknown. We will discuss these problems and their solutions as 
follows. 
 
2.4.1 Biosynthetic issues—getting collagen made and deposited in 
vitro 
 
The first challenge for in vitro fibrogenesis is the sufficient production of 
collagen and its subsequent incorporation into a pericellular matrix. Omission 
of ascorbic acid in cell culture [48, 73, 74] results in minimal production and 
deposition of collagen on the cell layer. Ascorbate is a crucial cosubstrate of 
the enzymes responsible for post-translational hydroxylation of prolyl and lysyl 
residues necessary for rendering the collagen triple helix thermostable, as 
well as for the extracellular cross-linking of collagen fibers, respectively [75, 
76].  In other words, scurvy can exist in cell culture, however, like its 
counterpart in vivo, it can be easily treated in vitro by the administration of 
ascorbate. However, L-ascorbic acid has a short half-life in culture and 
completely oxidizes after 3 days, so use of the stable form of ascorbate such 
as a magnesium salt of L-ascorbic acid 2-phosphate hexahydrate is highly 
recommended [75].  
 
About 23% of the collagen molecule is composed of proline and 
hydroxyproline. As a non-essential amino acid, proline is synthesized from 
arginine/ornithine via the urea cycle and glutamate (directly or indirectly from 
glutamine via glutaminase) through the citric acid cycle. Clinical observations 
in burn patients suggest a drain of arginine, ornithine and glutamate [77], 
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while wound fluid proline levels are at least 50% higher than plasma levels, 
suggesting active import of proline into the wound [78]. Providing additional 
proline or glutamine in the diet to enhance collagen biosynthesis, however, 
does not result in increased collagen accumulation. In contrast, arginine, and 
ornithine supplementation are most effective in increasing collagen deposition 
[79]. As cell culture media contains L-arginine and are usually supplemented 
with L-glutamine, direct proline supplementation of cell cultures in static and 
bioreactor conditions is not necessary for increasing collagens synthesis, as 
also shown recently [80]. However, systematic studies of proline-precursor 
supplementation in vitro under conditions of increased synthesis and 
deposition have yet to be conducted.  
 
Even under ascorbate supplementation, fibroblasts deposit only minimal 
amounts of secreted collagen I into their matrices. The reason for this lies in 
the tardy procollagen C-proteinase/BMP1 activity under current aqueous 
culture conditions. This results in an accumulation of unprocessed procollagen 
in the cell culture medium [2] where it does not belong, and is discarded with 
every medium change. Analytical methods have therefore mostly focused on 
the convenient measurement of procollagen secreted into culture medium. 
This may be sufficient to assess compounds that primarily influence 
biosynthesis and/or secretion, but it would not allow assessment of any later 
step in collagen matrix formation.  
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To improve collagen deposition in cell culture, a fibroplasia model was 
developed using hyperconfluent human dermal fibroblasts exposed to TGF-1 
for up to 1 month to allow the formation of a fibroplastic tissue [12]. In an 
abbreviated form (eight days TGF-1 treatment) this model is in use at Pfizer 
Global R&D (Sandwich, Kent). This model moves closer to emulating the 
entire collagen biosynthesis pathway as it allows the assessment of 
procollagen C-proteinase inhibitors, which are predicted to interfere with 
collagen deposition [13]. Destructive analysis of deposited collagen by HPLC 
of 4-hydroxyproline is performed on the insoluble culture fraction. Our 
laboratory has systematically developed technology to accelerate collagen 
deposition in vitro by introducing macromolecules into the culture medium. We 
have developed two deposition technologies that differ in terms of speed and 
morphology of the deposited collagen. The first approach employs charged 
macromolecules such as dextran sulphate 500 kDa (DxS) and polysodium-4-
styrene sulfonate [70]. DxS leads to a granular deposition of collagen within 
48-72 hrs, exceeding that of non-crowded cultures by 20- to 30-fold within the 
same time frame. The second approach using neutral macromolecules in a 
Ficoll cocktail (Fc) [68] increases collagen deposition 10-fold in six days and 
in a reticular deposition pattern (Chapter 3). Both approaches are based on 
the creation of the excluded volume effect as explained elsewhere [2, 70, 81]. 
Briefly macromolecules drive reaction partners into closer collaboration 
resulting in improved protein folding and protein-protein interactions. In the 
case of fibrogenic cell culture, the conversion of procollagen to collagen is 
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sped up as well as the supramolecular assembly of collagen triple helices to 
form fibers.  
 
2.4.2 Quantitative issues—measuring collagen and normalising 
the data 
 
Determination of the amount of collagen produced in vitro is the next 
challenge, and this can be done in a variety of ways ranging from simple 
colorimetric assays to elaborate chromatographic procedures using 
radioactive and non-radioactive material. What most of these procedures 
have in common is the need to destroy the cell layer to obtain solubilised 
collagen from the pericellular matrix. The oldest established colorimetric 
method employs chloramine-T method to measure hydroxypoline [82]. The 
destructive pre-solubilization requirement of collagen for this assay, lack of 
specificity in discriminating between collagen types, as well as a lack of 
internal normalization within samples, are disadvantages in a screening 
setting. The Sirius dye has been used since 1964 to identify collagen in 
histology specimens [83, 84]. It is based on the selective binding of Sirius Red 
F3BA to collagen. Subsequent elution with sodium hydroxide-methanol and 
read-out at 540 nm can be done in cuvettes, in microtiterplates with collagen 
extract adsorbed to the plastic and using microplate readers [74, 85, 86]. 
Biocolor Ltd (Northern Ireland) made the SircolTM Collagen Assay 
commercially available in 2007. Precipitation of soluble collagen with the 
Sirius Red dye is required prior to release of the dye with an alkali. In our 
hands, this assay grossly overestimates collagen and procollagen secreted 
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into cell culture medium due to interference of non-collagenous serum 
proteins, so we would recommend prepurification (peptic digest and 
ultrafiltration) to improve both sensitivity and specificity [87]. An interesting 
solution appears to be the adsorption of this dye onto collagen deposited on 
the cell layer in culture [88]. This was recently suggested in a modified version 
for the testing of antifibrotic agents [74], although this screening system did 
not use or recommend the addition of ascorbic acid [74]. Various enzyme-
linked immunoassays can be used to quantify specific collagen types such as 
coating collagen extracts onto multiwell plates followed by detection using 
antibodies, sandwich assays and competitive enzyme immunoassays. These 
assays are very suitable for assessing soluble collagen from culture media but 
would require extraction and dialysis procedures to release insoluble collagen 
from pericellular matrices.  In this case, normalization for differences between 
protein amounts or cell numbers in samples is not possible.  The 
determination of the hydroxyproline/proline ratio via high performance liquid 
chromatography is based on total hydrolysis of protein samples, separation of 
hydroxyproline from proline and back calculating the possible collagen content 
of the sample [89]. While this method allows for the analysis of any given 
biological material in experienced laboratories, it is not amenable to a 
screening setting and would not allow for normalisation or discrimination 
between different collagen types, the same holds true for metabolically 
labelled cell cultures with the attending issues of isotope handling [90]. Similar 
issues arise with gas chromatography/mass spectrometry requiring 
derivatization using trifluoroacetylation and methanol esterification of 4-
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hydroxyproline in collagen. Incorporation of the stable isotope of oxygen, 18O2, 
into collagen is also possible with this method and enables the examination of 
collagen synthesis in vitro [91]. Polyacrylamide gel electrophoresis can be 
very collagen specific using metabolic labelling of cell cultures with 
radiolabelled amino acids glycine and proline [92] and subsequent detection 
of radioactive bands using fluorography [93]. Metabolic labelling can be 
replaced with safer and very sensitive silver staining or immunoblotting [70]. 
The latter has the advantage of differentiating between various collagen types 
and comparison with an internal standard like actin as a cell mass equivalent 
for normalisation. Of note, collagen antibodies tend to recognise protein 
conformation in addition to sequence specificity, which can pose a problem for 
the detection of denatured collagen -chains in sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis (SDS-PAGE), hence native PAGE might 
be an alternative option [94]. All gel electrophoresis-based approaches are 
excellent qualitative and quantitative back-up techniques, however, their 
laboriousness would exclude them as screening tools.  
 
Normalisation of data to account for cell number variations is another 
important consideration and most of the methods discussed above lack the 
option of normalisation besides the use of parallel cultures subjected to 
separate measurement of total protein or DNA content. In any case, cell 
density influences the amount of collagen deposited. In fact, subconfluent 
cultures produce the most collagen [95]. Depending on the substance 
screened, inhibition or stimulation of proliferation, or cytotoxicity might occur. 
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As this certainly will impact on the collagen amount secreted/deposited, well–
to–well variances not withstanding, the acquired data must account for these 
changes in cell number/density. Data normalization methods involve 
destruction of cell layers to quantify housekeeping proteins by Western blot or 
DNA [89, 91]. This not only increases sample-processing steps, but also 
cumulates error.  
 
2.4.3 Qualitative issues—looking beyond collagen I 
 
(5) Fibrosis is not only characterised by an excess built-up of collagen I but 
depending on the tissue context other proteins might be of interest. Also, the 
transition of fibrogenic cells from a quiescent fibroblast stage to a fibrotic 
myofibroblast phenotype should be considered. Markers like -smooth muscle 
actin or fibroblast activation protein- [96] are up-regulated in stimulated 
fibroblasts, and a survey of the production and deposition of non-collagenous 
ECM proteins as an internal control for the action of antifibrotic agents, would 
be desirable. In addition to capturing the actual number of cells in a given well, 
options for a high content read-out covering as many of the above markers as 
possible in addition to collagen I would constitute an ideal antifibrotic 





We have reviewed current methods of cell culture and collagen quantitation 
vis-à-vis the high content options and requirements for normalization against 
cell number for meaningful data retrieval. Only when collagen has formed a 
fibrillar matrix that becomes cross-linked, invested with ligands, and can be 
remodeled and resorbed, the complete picture of fibrogenesis can be reflected 
in vitro. A well thought-out in vitro fibrogenesis system represents the missing 
link between brute force chemical library screens and rational animal 
experimentation, thus providing both cost-effectiveness and streamlined 




Even with options to screen antifibrotics in vitro, in vivo testing is inevitable. 
We must acknowledge the limitations of current in vitro screening systems in 
order to improve on future technology. At the present moment, we have 
greatly simplified fibrogenesis in order to develop a basis for assessment of 
compounds in vitro. For example, it is difficult to mimic the clearance of drugs 
in a complex organism, but this will definitely affect the performance of a drug 
and may explain discrepancies between in vitro and in vivo data. Interestingly, 
the spotlight is shifting from collagen-producing myofibroblasts as the master 
“producers” of fibrosis, to macrophages as “regulators” of fibrosis [97]. This 
presents another level of complexity if a foreign body reaction or an immune 
reaction were to be imitated in a Petri dish. The progression of hypoxia and 
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fibrosis in liver disease [98] is also impossible to reproduce in vitro with 
current methods. Recently, Terashima et al, 2010, proposed the use of 
collagen I reporter transgenic rats, with luciferase activities corresponding to 
hydroxyproline content in various organs, for the screening of antifibrotics 
within 7 days, as well as organ culture of glomeruli from these rats as an in 
vitro assay [99]. It is slightly disturbing that animals are being refined for 






















The downstream effect of fibrosis is the increase of collagen I content in a 
tissue, organ or surrounding an implant. This chapter introduces a new in vitro 
screening method focused on collagen I deposition normalized to cell 
numbers, and the constraint of poor ECM deposition in cell culture is 
overcome by employing the technology of macromolecular crowding. 
 
Part of this chapter has been adapted from the candidates publications: 
Chen CZ, Peng YX, Wang ZB, Fish PV, Kaar JL, Koepsel RR, Russell AJ, Lareu RR, 
Raghunath M: The Scar-in-a-Jar: studying potential antifibrotic compounds from the 
epigenetic to extracellular level in a single well. British Journal of Pharmacology 
2009, 158:1196-1209. 
 
Chen C, Loe F, Blocki A, Peng Y and Raghunath M. Applying the principle of 
macromolecular crowding to enhance the extracellular matrix deposition and 
remodelling in vitro for tissue engineering and cell-based therapies. Advanced Drug 
Delivery Reviews  2010 (In press) 
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 3.1 Background 
 
Scarring is a physiological tissue response to wounding which has been 
highly conserved in evolution and across species. As the last phase of wound-
healing, it is usually self-contained. However, if this phase is perpetuated by 
repeated tissue insults and/or ongoing inflammation, fibrosis ensues. Fibrosis 
is histopathologically characterised by an excessive production and deposition 
of collagen that converts normal tissue into scar tissue with associated loss of 
function. Therefore, causes as diverse as chronic infections, radio -and 
chemotherapy, chronic exposure to alcohol and other toxins can all lead to 
fibrosis with a considerable global disease burden. It is estimated that there 
are 5 million cases of lung fibrosis worldwide [15]. A major cause for liver 
fibrosis is chronic hepatitis virus B and C infection. 1 million people die every 
year from complications of chronic HBV, mainly primary hepatocellular 
carcinoma and liver fibrosis. Of those exposed to HCV, 12% (about 24 Mio) 
develop liver cirrhosis, placing it currently at rank 18 of global disease burden 
[16]. Besides afflicting whole organs, localized fibrosis can severely impair the 
quality of life in millions of patients, for example through implant failure caused 
by peri-implantational fibrosis [3, 4].  
 
The development of effective antifibrotics is therefore an important unmet 
clinical need. Rapid in vitro screening of lead compounds before they are 
tested in animal models will hasten the development process. However, this 
has been severely hampered by biological and technical problems. Firstly, 
fibrogenic cells in monolayer culture do not lay down significant amounts of 
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collagen in a useful time window for screening. It is still not widely known that 
this is due to a tardy enzymatic conversion of procollagen to collagen in vitro 
even under full procollagen synthesis [2]. On the basis of this previously 
unsolved biological problem, analytical methods have mostly settled for the 
measurement of procollagen secreted into culture medium, but these 
conditions barely mimic a fibrotic situation. So to address this, prolonged 
cultures (4-6 weeks) or hyperconfluent cell culture fibroplasia models (FP) [12] 
incorporating transforming growth factor 1 (TGF1) to stimulate fibroblast 
proliferation and collagen production, have been developed. FP currently is 
the testing standard in industry [13]. Secondly, cell number quantitation 
required for data normalization currently requires the destruction of cell layers 
in order to normalize against protein or DNA [89, 91]. Minimally deposited 
collagen in the extracellular matrix (ECM) must be solubilized prior to analysis 
[94, 100], and this also applies to the FP model [13]. Thirdly, collagen 
quantitation based on the popular picro-sirius red dye assay [74] is non-
specific. It has low sensitivity in conditions of minimal collagen deposition, and 
is reliable only after a prepurification step [87]. The tedious determination of 
hydroxyproline content is far more collagen-specific but of limited sensitivity. 
Other methods which rely on laser scanning confocal microscopy [101] are 
slow during image acquisition and not suitable for handling multi-well plates.  
 
Lastly, antifibrotics should preferably target collagen, along with additional 
features characteristic for fibrosis such as -SMA expression in 
myofibroblasts and epithelial-mesenchymal transition. Therefore, it would be 
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desirable to quantitate simultaneously non-collagenous proteins and cell 
proliferation. For the first time, optical analysis and quantitation of enhanced 
collagen deposition has been utilised as a non-destructive, rapid and protein 
specific tool in a single-well format for the screening of antifibrotic compounds. 
 
The Scar-in-a-Jar implements for the first time in vitro the complete 
biosynthetic cascade of collagen matrix formation including complete 
conversion of procollagen by collagen C-proteinase/BMP-1, its subsequent 
extracellular deposition and lysyl oxidase-mediated cross-linking. This is 
achieved by applying the biophysical principle of macromolecular crowding. 
All living systems are highly crowded  [102]. This is true of the interiors of 
cells, whether bacterial, animal, or plant, and the exterior of most cells of 
multicellular organisms. The crowding element is derived from 
macromolecules such as proteins, carbohydrates, lipids and nucleic acids, 
that form macromolecular complexes and supramolecular assemblies such as 
cellular organelles and membranes [103]. Although up to 40% of the 
cytoplasmic volume can be occupied by macromolecules [104, 105], the usual 
range lies between 20–30% [106]. Notably, the volume-occupying 
macromolecules also tend to have a net fixed electrical surface charge. The 
earliest life forms (viruses, archaea and prokaryotes) have been found to have 
crowded structural and functional units. The total concentration of protein and 
RNA inside bacteria like E. coli is in the range of 300-400 g/L. As we go up the 




Macromolecular crowding functions by way of the excluded volume effect 
(EVE) and is often referred to as the “volume of a solution that is excluded to 
the center of mass of a probe particle by the presence of one or more 
background particles in the medium” [107]. Fractional volume occupancy  
denotes the fraction of the total volume occupied by macromolecules. 
Thermodynamically, volume exclusion lowers the configurational and 
conformational freedom (entropy) leading to elevated basal free energy of the 
reactant macromolecules and a number of downstream effects [108]. These 
may be identified as (1) folding of biopolymers (e.g. proteins and nucleic 
acids) into native states optimal for function [109], (2) stronger 
macromolecular transition complexes with longer half-lives (eg. enzyme-
substrate) leading to more product, and (3) buffering effect of crowded 
environments on biological function under conditions of adverse pH, 
temperature or ionic strength [110]. Biological reactions performed in dilute in 
vitro conditions proceed at significantly tardier rates than their in vivo 
counterparts [111]. However, MMC and EVE have not been appreciated in the 
biological domain and applications are yet to be fully developed and 
implemented [112].  
 
For our intents and purposes, we define a macromolecule within the realm of 
EVE in biological systems to have a molecular weight (MW) in the range of 50 
to 500 kDa, with a hydrodynamic radius RH between 5 to 50 nm. Structurally 
and chemically, the macromolecule could be derived from any representative 
of the carbohydrate/ protein/nucleic acid/lipid family. However, the crowding 
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behaviour is entirely dependent on the physical property of the 
macromolecule. The density or crowdedness of macromolecules is 
determined by approximation of solute content. For the interior of cells, 
concentrations of macromolecules have been determined to be in a range 
from 50 to 400 mg/mL [113]. This concentration refers to the cumulative 
concentration of all species of macromolecules present, rather than the 
concentration of any single macromolecule. The presence of these 
macromolecules means that they significantly occupy space in the given 




Biological macromolecules such as enzymes and proteins function in highly 
crowded environments. Crowding and EVE are thus inevitable requirements 
for life and typical of the intra- and extracellular milieu. Cell culture is a typical 
example, where cells anchored to a culture plate find themselves bathed in an 
ocean of medium that is hardly representative of its in vivo microenvironment. 
MMC can be mimicked experimentally by adding inert synthetic or natural 
macromolecules to a system in vitro [112]. As a result of the mutual 
impenetrability of solute molecules (Pauli Exclusion Principle), steric 
repulsions are generated and this affects the activity of a solute - which is 
highly dependent on its steric freedom or the volume that is available to the 
centre of mass of each molecular species. This is the most fundamental of all 
interactions between macromolecules in solution and is always present at 
finite concentration, independent of the magnitude of additional electrostatic or 
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hydrophobic interactions. It is conceivable that the addition of the inert 
crowders to occupy a significant volume fraction in the medium will place 
constraints on the active factors present in the microenvironment, thus driving 
associations and reactions [112, 113]. 
 
By applying MMC, we found that the collagen matrix deposition velocity and 
morphology can be controlled using negatively charged crowders in a rapid (2 
days) mode and a mixture of neutral crowders in a novel accelerated (6 days) 
mode. Combined together with quantitative optical bioimaging, this novel 
system allows for a non-destructive, rapid and protein specific in situ 
assessment of the area of deposited collagen(s)/cell in a single-well format for 
the screening of antifibrotic compounds. 
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3.2 Materials and Methods 
 
3.2.1 Fibroblast Cell culture 
 
Normal primary lung fibroblasts were selected on the basis of their strong 
collagen I production in our hands. The cells were routinely cultured at low 
passage (3-8) as outlined earlier [2]. Fibroblasts were seeded on 24-well 
plates at 50,000/well in 10% FBS, 5% CO2 at 37
oC. After 16 hours, the 
medium was changed to DMEM containing 0.5 % FBS, 100 μM of L-ascorbic 
acid phosphate magnesium salt -hydrate with or without 500kDa dextran 
sulphate (DxS –rapid mode) at 100 μg mL-1 or a mixture of 37.5 mg mL-1 Ficoll 
70 with 25 mg mL-1 Ficoll 400 (Fc –accelerated mode), 5 ng mL-1 TGF1, and 
in combination with or without antifibrotic substances. Only 2,4-
pyridinedicarboxylic acid monohydrate (PDCA) and -aminopropionitrile 
(BAPN) were added daily to Fc crowded cell cultures (accelerated mode). 
Other substances were added in a one-time dosage.  
 
1 μM Trichostatin A (TSA), 300 mM PDCA dissolved in ddH2O with 655 mM 
sodium bicarbonate (Sigma-Aldrich, St Louis, MO) to neutralize the pH, was 
prepared and diluted to a working concentration of 10 mM PDCA in medium.  
0.5 M ciclopirox olamine (CPX) stock was prepared in methanol and diluted to 
a working concentration of 1 mM CPX in DMEM prior to cell culture addition 
with a final concentration of 8 μM.  IC50 values and references for respective 
inhibitors are given below (Table 2). A 100 mM stock of C-proteinase inhibitor, 
PCP56, in DMSO was added to cell culture media to get a final concentration 
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of 10 μM PCP56. A stock of 10 mM -aminopropionitrile (BAPN) was freshly 
prepared in doubly-distilled water and was added to cell culture media to get a 
final concentration of 0.1 mM BAPN. ECM was deposited under crowded 
conditions (DxS 2 days and Fc 6 days) prior to addition of 300 μL of 
recombinant catalytically active human MMP1 (0.17 mg mL-1 or 50μg/24-well) 
(50 mM HEPES, 10 mM CaCl2, pH 7.5 buffer). Digestion was carried out for 
16 hours at 37oC. 
 
3.2.2 Fibroplasia models 
 
Fibroplasia model 1 [12]: WI-38 fibroblasts were seeded at a density of 
100,000 cells/24-well and incubated for 3 days in DMEM containing 0.4% 
FBS, 5% CO2 at 37
oC. The cells were then treated with DMEM containing 10% 
FBS, 100 μM L-ascorbic acid phosphate magnesium salt -hydrate in the 
presence or absence of 300pM TGF1 for 14 days, with a media change 
every 4 days.  
 
Fibroplasia model 2 [13]: WI-38 fibroblasts were seeded at confluency in 24-
well plates (100,000 cells/well/mL) and cultured in DMEM containing 10% 
FBS, 100 μM of L-ascorbic acid phosphate magnesium salt -hydrate and 3 
ng mL-1 TGF1, at 5% CO2 at 37oC. Medium was changed twice a week and 




3.2.3 Optical analysis 
 
A bioimaging station comprising of a Nikon TE600 fluorescence microscope 
plus Xenon illuminator (LB-LS/30, Sutter Instrument Company, CA, USA), with 
an automated Ludl stage (BioPrecision 2, Ludl Electronic Products Ltd, 
Hawthorne, NY) and shutter, and equipped with a Photometrics CoolSNAP 
high sensitivity cooled monochrome charge-coupled device camera (model 
HQ, Roper Scientific, Pleasanton, CA) was used. Screening of 24-well 
multiwell plates was made possible by an automated stage and autofocus 
capabilities. Nine image sites per well were acquired at 20x magnification, 
stored and analyzed using the Metamorph ® Imaging System software 
(Molecular Devices, Sunnyvale, CA). An image field of 4.48 x 3.34 mm per 
site was defined for each 24-well to obtain an image spread of 13.43 x 10.03 
mm (134.70 mm2) per well. The Count Nuclei module was used for cell 
enumeration with specific parameters in order for a region to be considered as 
a positive count (countable nucleus): 1) Areas with pixel intensity value 15 
above that of the background, 2) fluorescent areas with a minimum length of 
10 μm and a maximum length of 15 μm. The Integrated Morphometry 
Analysis module was used to quantify the area of fluorescent collagen I 
staining which had been deposited on the cell layer. Experimental controls 
were used to determine suitable fluorescent intensity thresholds (300 for the 
DxS mode and a range between 500-550 for the Fc mode) fluorescent signals 
below a defined pixel intensity value were thresholded out, which eliminated 
measurement of the background area. Triangle masks were added to 
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eliminate quantitation of corner auto-fluorescence. This analysis resulted in a 
data set expressed as area of collagen I per nuclei in μm2 per image field.  
3.2.4 Immunocytochemistry  
 
Cell layers were fixed with methanol and blocked with 3% bovine serum 
albumin in phosphate-buffered saline (PBS). Primary antibodies were 
incubated for 1.5 hours followed by washing three times with PBS. Secondary 
antibodies and DAPI were incubated for 30 minutes and washed three times 
with PBS. Antibodies used were: mouse anti-human collagen I monoclonal 
primary antibody and rabbit anti-fibronectin, along with AlexaFluor 594 goat 
anti-mouse and AlexaFluor 488 chicken anti-rabbit secondary antibodies. Cell 
nuclei were stained with DAPI.  
3.2.5 Biochemical analyses- Sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Triplicate protein samples were pooled and resolved under non-reducing 
conditions using in-house 5% resolving/3% stacking polyacrylamide gels on a 
Mini-Protean 3 as outlined in Raghunath et al. [93]. Protein standards used 
were the Precision Plus Dual Colour and Prestained Broad Range, and 
collagen type I standards. Protein bands were stained with the SilverQuest™ 
kit according to the manufacturers protocol. Densitometric analysis of wet 
gels was performed on both collagen 1(I)- and 2(I)-bands with a GS-800™ 





3.2.6 Western blotting 
 
Proteins were extracted from the cell layer, subjected to non-reducing- SDS-
PAGE using in-house 4% resolving/3% stacking or 10% resolving/3% 
stacking polyacrylamide gels on a Mini-Protean 3. Proteins were 
electroblotted onto nitrocellulose membrane and immuno-detection was 
carried-out in tris-buffered saline Tween-20 pH 7.6 (50 mM Tris-base 150 mM 
NaCl/0.05% Tween 20) with 5% non-fat milk. Mouse anti-human procollagen 
type I C-propeptide was used at 5 μg/mL, mouse anti-hsp47 was used at 1 
μg/mL, mouse anti--actin was used at 1 μg/mL, and incubated for 1.5 hours.  
Subsequently, a secondary goat anti-mouse conjugated to HRP (Thermo 
Scientific, Rockford, IL) was used at 1/1000 dilution for 1 hour. The signal was 
detected by chemiluminescence and captured with a VersaDoc Imaging 
System model 5000.  
3.2.7 miRNA transfection  
 
20 nM of mimic miR29c (M29c) and inhibitor miR29c (I29c) were transfected 
into fibroblasts using lipofectamine RNAiMax (Invitrogen, Grand Island, NY) 
diluted with Opti-MEM® I reduced serum medium according to the 
manufacturers forward transfection protocol, prior to addition of DxS. Mock 
transfection samples were only treated with lipofectamine and Opti-MEM® I 
without any RNA. 
3.2.8 Statistical Analysis  
 
Data are presented as means ± s.d. and as fold changes of relevant controls. 
The statistical significance between groups was determined by students t-test 
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using a two-tailed distribution with unequal variance. An effect was considered 
significant when 1.0 did not belong to the 95% confidence interval of the 
collagen I amount in comparison with controls. (*p value <0.05) 
3.2.9 Materials 
 
WI-38 fibroblasts were obtained from American Tissue Culture Collection 
(CCL-75, VA, USA). Cell culture media and serum were obtained from 
Invitrogen (Grand Island, NY). All cell culture plastic ware (CELLSTAR®) was 
purchased from Greiner BioOne (Frickenhausen, Germany). L-ascorbic acid 
phosphate magnesium salt -hydrate was obtained from Wako (Osaka, 
Japan). All macromolecules were purchased from GE Healthcare 
(Buckinghamshire, England), and TGF1 from R&D Systems (MN, USA). 
TSA, PDCA CPX, BAPN and sodium bicarbonate was from Sigma-Aldrich (St 
Louis, MO), PCP56 (UK-421,045: (3R)-6-Cyclohexyl-N-hydroxy-3-(3-[114]-
1,2,4-oxadiazol-5-yl)hexanamide)) was from Pfizer Global Research and 
Development, (Sandwich, Kent) and recombinant MMP-1 corresponding to 
residues 101 – 469 in the full-length enzyme, was produced and purified by 
Aldevron, LLC (Fargo, ND) as previously described [58]. The collagen I and 
fibronectin antibody was from Sigma-Aldrich (St Louis, MO), and Dako 
(Glostrup, Denmark) respectively. All secondary antibodies for 
imuunocytochemistry and DAPI were purchased from Molecular Probes 
(Eugene, OR, USA). SDS-PAGE reagents and equipment were obtained from 
Bio-Rad Laboratories (Hercules, CA), collagen type I standards were from 
Koken Co. (Tokyo, Japan). The SilverQuest™ kit was from Invitrogen (Grand 
Island, NY). For immunoblotting, the procollagen type I C-propeptide antibody 
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was from QED biosciences (San Diego, CA). The Hsp47 antibody was from 
Enzo Life Sciences (Plymouth meeting, PA). The -actin antibody was from 
Sigma-Aldrich (St Louis, MO). Secondary antibodies and chemiluminescence 
substrate were from Pierce Biotechnology (Rockford, IL). Reagents used for 
miRNA transfection were from Invitrogen (Grand Island, NY) and both 
precursor and inhibitor miRNAs were purchased from Ambion (Foster City, 
CA). 
 
Table 2 IC50 of tested compounds 
Compound IC50 
HDAC1: 6.0 ± 2.5 nM 
HDAC4: 38 ± 4 nM 
Trichostatin A [115] 
HDAC6: 8.6 ± 1.4 nM 
2,4-pyridinedicarboxylic acid [116]  2.2 mM 
Ciclopirox olamine [117] 5.0 μM 
FSY002 [118] 3 nM 
PCP56 [13] 11 nM 




3.3.1 Choosing the adequate human cell lines and their properties  
We initially assessed well-characterized normal human embryonic cell lines 
IMR-90 and WI-38 because they grow reliably for a number of passages and 
deposit substantial amounts of collagen (1-2 μg per 1.9 cm2, not shown). WI-
38 was selected because it showed a slower proliferation rate which was 
preferable for adherent cytometry for the accelerated mode (see below, and 
Figure 4). WI-38 fibroblasts remained subconfluent under the specified culture 
conditions throughout the length of our study.  
 
 
Figure 2 Accelerated matrix formation under neutral macromolecular crowding 
at day 2, 4 and 6 analyzed by densitometry and optical analysis. (A) 
Densitometric evaluation of SDS-PAGE gels revealed over 6 days that a 2-fold and 
6.5-fold increase of collagen I deposition had occurred in the absence and presence 
of TGF1, respectively (B) Collagen I on the cell layer was immunostained and 
quantified using optical analysis. Over 6 days, collagen I deposition was enhanced 2-
fold and 9-fold in the absence and presence of TGF1, respectively. Densitometry 
data were calculated from pooled triplicate samples and optical analysis data were 
expressed as mean ± s.d., as fold change in comparison with non-crowded controls. 
Figure from supplementary data of [10]. 
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3.3.2 Implementation of two collagen deposition protocols  
 
Crowding of culture medium with dextran sulphate served as the rapid 
deposition mode (DxS), as it yields maximal granular deposition of collagen I 
by 48 hours exceeding that in conventional cell cultures within the same time 
frame by more than 20-fold [70]. This increase was confirmed optically, with 
high correlation to quantitative SDS-PAGE gels of peptic cell layer extracts 
(Figure 3a and 6d). The enhanced conversion of procollagen to collagen by 
procollagen C-proteinase/BMP1 was confirmed by immunoblotting (Figure 
3b). 
 
TGF1 further increased collagen I deposition by another 1.5-2 fold on top of 
the deposition gain observed in cultures treated with DxS alone (Figure 3d-e). 
Crowding of culture medium with neutral mixed ficoll served as the 
accelerated mode (Fc), and six days culture resulted in the doubling of 
collagen deposition in comparison to non-crowded cultures (Figure 2), and an 
additional 2-fold increase in the presence of TGF1 in comparison with non-
TGF1 crowded cultures (Figure 3d-e). Moreover, this mode resulted in a 
fibrillar collagen meshwork with a more even spread of immunosignal (Figure 
1c-vii and viii, xiii and xiv). Rapid mode (-TGF1) (2 days) and accelerated 
mode (+TGF1) (6 days) outperformed both FP models (+TGF1)  (18 days 





Figure 3 Rapid and accelerated collagen deposition modes versus in vitro 
fibroplasia. (a) Silver stained SDS PAGE: markedly increased collagen deposition in 
the presence of DxS (b) procollagen C-propeptide immunoblot shows intact secreted 
procollagen in routine culture, and complete cleavage of procollagen C-propetide in 
the presence of DxS (c) Immunocytochemistry: standard culture with reticular 
fibronectin matrix and minimal collagen I deposition (i-iv), Fc (accelerated): enhanced 
reticular collagen I/fibronectin matrix (vii-x). DxS (rapid): granular aggregates of 
collagen I/fibronectin (xiii-xvi) with highest ECM content (x400 magnification). (d) 
SDS-PAGE analyses of collagen matrix content in both deposition modes in the 
absence/presence of TGF1 and fibroplasia models. With TGF1 both deposition 
modes give more and faster matrix formation including stronger lysyl oxidase-
mediated cross-linking than both FPs. Note presence of collagen V in FP and 
accelerated mode and its absence in rapid mode. (e) Densitometric evaluation of  (d). 
Figure from [10]. 
 
3.3.3 Image Processing and Capturing 
 
Methanol fixation was the method of choice for immunostaining (Figure 5). 
Nine image fields would quantify 70% of the total well area (190 mm2) in a 24-
well plate (Figure 6a-i). Since the curvature of the wells created artificial 
reflection and increased auto-fluorescence in the four corner fields (Figure 6a- 
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ii), macros were written that added triangular masks to conceal these regions 
during quantitation (Figure 6a-iii and iv). Taking into account cell distribution 
irregularities close to the well edges that have to be excluded from analysis, 
the final quantitation area represents 83% of the relevant area (105 mm2 –
54% of the total well area) (Figure 6a-iv). A long-range 2x objective (20x total 
magnification) renders the bioimaging station independent of the use of 
expensive optical plates. A 24-well format was selected as the 96-well format 
 
Figure 4 Correlation of rapid (DxS) and accelerated (Fc) collagen deposition 
modes with cell density by the optical analysis method. (a) Rapid mode: under 
DxS treatment the total area of deposited collagen I shows a sigmoidal increase and 
the total collagen I deposited peaks at 50,000 cells/24-well. (b) The area of collagen I 
deposition/cell peaks at 25,000 cells/24-well. (c) Accelerated mode: under Fc 
treatment total area of collagen I deposition increased exponentially from 10,000 
cells/24-well onwards. (d) The area of collagen I/cell shows a similar exponential 
behaviour (c). Figure from supplementary data of [10]. 
 
resulted in higher well-to-well variances of cell distribution (not shown). 
Quantitation of nuclei and the area of collagen I was demonstrated in figure 
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6c. Optical analysis to quantify both area and fluorescence intensity of 
collagen I per cell was compared with densitometric measurements of silver 
stained SDS PAGE collagen I bands (Figure 6d). The results were found to 
correlate closely, hence area was selected to be a measure of collagen I 
deposition. A variation of 10% in cell numbers was contributed by cell seeding 
errors, and the image acquisition and enumeration errors were considered 
negligible (<<0.3%) (data not shown). 
 
3.3.4 Testing known and novel antifibrotics in comparison with 
SDS PAGE 
 
Known and novel agents with anti-fibrotic potential were employed to interfere 
with various key steps along the collagen biosynthesis pathway. Reduction of 
collagen I deposition relative to untreated controls in both deposition modes 
was used as a read-out for antifibrotic efficacy. Optical analyses for all 
antifibrotic substances were validated by biochemical analyses illustrated in 
figure 6, 7, 13 and 14 and a very good correlation was determined between 
optical and densitometric quantitation (data not shown). 
 
3.3.4.1 Epigenetic interference with collagen deposition  
 
TSA, a histone deacetylase inhibitor, was previously suggested as a potential 
antifibrotic compound [120]. In the absence of TGF1, TSA reduced collagen I 
deposition to 60% (rapid) and 43% (accelerated). In the presence of TGF1, 
collagen I was reduced to 65% (rapid) and 29% (accelerated), close to 
baseline amounts of normal conditions without TGF1 (Figure 7a-b). 
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Fibronectin signal remained unchanged (Figure 7c-d), but cell proliferation 
was inhibited (Figure 7e).  
 
Figure 5 Preservation and quantitation of deposited collagen I and cell 
enumeration is dependent on the fixative used. (A-C) Comparisons between live 
staining, 4% PFA and MeOH fixation (A) MeOH yielded the greatest quantified area 
of collagen I deposited, followed by live staining and 4% PFA as the lowest. (B) 
Adherent cell enumeration revealed cell loss during live staining with the lowest cell 
retention level in comparison with 4% PFA and MeOH (C) The area of collagen I/cell 
was calculated for normalization purposes. Figure from supplementary data of [10]. 
 
 
3.3.4.2 Post-transcriptional interference with collagen deposition  
 
We had recently predicted microRNA 29c to target procollagen 1(I) mRNA by 
the rna22 algorithm [14] and tested mimic and inhibitor miR29c in the rapid 
deposition mode. Both negative controls (scrambled oligos) did not affect 
collagen I deposition. In contrast, M29c reduced collagen I deposition in the 
absence of TGF1. Particularly in the presence of this growth factor, 10 nM 
and 1 nM M29c reduced collagen I to 13% and 28% of mock transfected 





Figure 6 Image acquisition and quantitation of rapid collagen deposition mode. 
(a) (i) 20x magnification of cells in a 1.9 cm2 well with superimposed original 
rectangular image acquisition area (red box). (ii) enlarged red box: corner auto-
fluorescence (arrows). (iii and iv) acquisition area after application of triangular 
masks to eliminate corner auto-fluorescence (b) Shading correction for non-
homogenous fluorescence during image acquisition for unbiased quantitation at 20x 
magnification. (i) non-homogenous fluorescence background. (ii) fibronectin 
immunofluorescence acquired with uneven fluorescence. (iii) same image after 
background fluorescence removal. (c) Cytometry and quantitation of the area of 
deposited collagen I. (i) DAPI-stained nuclei at 20x magnification in monochrome 
pseudocolor, scale bar, 1 mm. 600x magnification (inset). (ii) red scored nuclei by 
Count Nuclei module for cytometry. (iii) immunostained deposited collagen I. (iv) 
regions with fluorescent pixel intensity above a selected value based on controls are 
demarcated by the software in green for quantitation of deposited collagen I area at 
100x magnification. (d) Densitometry versus image analysis for collagen I 
quantitation. Optically, fluorescence intensity (FIT) and area were similar; correlating 
well with densitometry. TGF1-induced increase of collagen I deposition was 
detected in similar amount and tendency optically and biochemically. Data are 
expressed as mean ± s.d., calculated from triplicates and as a relative percentage of 




reduced by M29c and in the presence of TGF1 (Figure 8b). I29c did not 
cause a significant change in collagen I deposition, but caused a reduction of 
deposited fibronectin in the presence of TGF1 (Figure 8a-b). Cell 
proliferation was not inhibited (Figure 8c). Col1A1 gene expression was 
significantly reduced by 10 nM M29c to 15% and 45% (TGF1) (Figure 8d). 
Hsp47, a collagen chaperone, was also a target for M29c. 10 nM, 20 nM and 
50 nM M29c reduced this protein to 34%, 36% and 49% in comparison with 
controls without TGF1 treatment, and to 38%, 40% and 34% in the presence 
of TGF1 (Figure 8e-f). 
 
3.3.4.3 Post/Co-translational interference with collagen deposition 
 
Collagen prolyl-4-hydroxylase inhibitors like 2,4-PDCA [116] and CPX [117] 
render collagen triple helices less thermostable and thus prevent their 
secretion. Reduction of collagen I was observed in both deposition modes 
(Figure 9a-b). Particularly in the presence of TGF1, 2,4-PDCA reduced 
collagen I deposits to 24% (rapid) and 23% (accelerated). In the absence of 
TGF1, CPX reduced collagen I to 2% (rapid) and 20% (accelerated), and in 
the presence of TGF1, to 1% (rapid) and 12% (accelerated) (Figure 9c-d). 
Either inhibitor did not significantly reduce fibronectin deposition (Figure 9e-f), 
and both compounds appeared to dampen cell proliferation moderately 
(Figure 9g). Effects of the hydrophilic 2,4-PDCA were evident in the 
accelerated mode only if added daily after the first 48 hrs. In contrast, the 




Figure 7 Epigenetic interference of collagen deposition. Area of collagen I (a) 
was normalized to cell numbers (b). TSA reduced collagen I/cell to 60% (control, p = 
0.02) and 65% (TGF1, p = 0.001) in rapid mode, and 43% (control, p = 0.007) and 
29% (TGF1, p = 0.004) in accelerated mode. Comparing area of Fn (c) with area of 
Fn/cell (d) highlights the importance of normalization to cell numbers. In rapid mode, 
TSA did not change Fn area/cell, but doubled it in the accelerated mode. TSA 
reduced cell numbers (e) to 65% (DxS, p = 2.52 x 10-5), 75%  (DxS+TGF1, p = 
0.001), 47% (Fc, p = 0.0005) and 43% (Fc+TGF1, p = 0.003). *p < 0.05 versus 
respective controls. Data are expressed as mean ± s.d., calculated from triplicates 





Figure 8 Post-transcriptional regulation of collagen deposition. (a) Mimic 
miRNA29c (M29c): scrambled controls 1,2 or inhibitory miR29c (I29c) did not affect 
collagen deposition. However, M29c reduced it to 13% and 28% (TGF1, p = 0.003 
and p = 0.003). (b) area of Fn/cell was significantly reduced in the presence of 
TGF1 by M29c, as well as by 10 nM I29c to 43% (p = 0.024), 45% (p = 0.016) and 
57% (p = 0.043) respectively. (c) Cell numbers were unaffected. (d) qPCR was used 
to demonstrate that M29c reduced collagen I gene expression  to 15% (p = 0.0006) 
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and 45% (TGF1, p = 0.004) in comparison with mock samples. (e) an immunoblot 
for heat shock protein 47 (hsp47) also demonstrated that it is a target of M29c. (d) 
densitometry quantified that treatment with 10 nM, 20 nM and 50 nM M29c reduced 
hsp47 to 34%, 36% and 49% respectively without TGF1, and to 38%, 40% and 34% 
with TGF1.   *p < 0.05 versus respective controls. Data are expressed as mean ± 
s.d., calculated from triplicates and as -fold changes over respective controls. Figure 
adapted from [10], (d-f) are new data. 
 
3.3.4.4 Post-secretional interference with collagen deposition  
Procollagen C-proteinase/BMP1 controls the supramolecular assembly of 
collagen into fibrils via removal of the C-terminal propeptide from the 
procollagen I molecule. Optical analysis reported that the sulfonamide PCP56 
reduced the deposited area of collagen I to 40% (rapid) and 52% 
(accelerated), and in the presence of TGF1 to 82% (rapid) and 43% 
(accelerated). Only in the rapid mode was fibronectin reduced, to 46% 
(control) and 36% (TGF1) (Figure 10a-b). The accelerated mode showed a 
17% decrease in cell numbers with PCP56 in the presence of TGF1.  
 
Although cell numbers were reduced, the absence of detached cells 
suggested slower proliferation rather than toxicity (Figure 10c). Biochemical 
analysis demonstrated that PCP56 treatment also resulted in accumulation of 
procollagen in the medium (Figure 10d-e). 
 
BAPN irreversibly inhibits lysyl oxidase, an amine oxidase that is crucial in 
stabilising ECM by cross-linking collagen chains [119]. In both deposition 
modes, BAPN caused no reduction of area collagen I/cell (Figure 11a), but the 
area of fibronectin/cell was reduced to 62% (rapid) and 69% (accelerated) in  
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Figure 9 Optical analyses of the effects of co-translational inhibition of prolyl 
hydroxylase on collagen I deposition. (a-b) Immunocytochemistry: perturbed ECM 
formation in both deposition modes at 100x magnification. Area of collagen I (c) 
normalized to cell numbers (d). PDCA significantly reduced collagen I deposition, 
particularly in the presence of TGF1, in both modes. Collagen I/cell dropped to 24% 
(DxS, p = 0.015) and 23% (Fc, p = 0.005). 8 μM CPX diminished collagen I area to 
2% (control, p = 0.013) and 1% (TGF1, p = 0.001) in the rapid mode, and 20% 
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(control, p = 1.26 x 10-5) and 12%  (TGF1, p = 0.0006) in accelerated mode. (e) 
CPX caused a significant decrease of fibronectin area in rapid mode, after 
normalization only in presence of TGF1 (62%, p = 0.005) (f). CPX also caused a 
significant increase in the area of Fn/cell in accelerated mode, to 256% (control, p = 
0.003) and 247% (TGF1, p = 0.007) and showed (g) anti-proliferative effects. *p < 
0.05 versus respective controls. Data are expressed as mean ± s.d., calculated from 
triplicates and as -fold changes over respective controls. Figure from [10]. 
 
the absence of TGF1 (Figure 11b). Cell proliferation was not affected (Figure 
11c). SDS-PAGE revealed a reduction of -bands representing less cross-
linked collagen I -chains (Figure 11d-e), to 26% (control) and 33% (TGF1) 
in rapid mode, and 62% and 32% (TGF1) in accelerated mode by 
densitometry (Figure 11f-g). 
 
MMP1 controls collagen turnover in the ECM [121] by cleaving collagen at a 
single site. Cell layers with ECM created under both deposition modes were 
exposed to exogenous recombinant MMP1. We observed detachment of cells 
during MMP1 treatment especially in matrix derived from the rapid mode 
(Figure 12c). Therefore, the total area of collagen I/well was quantified without 
normalisation for cell numbers. MMP1 reduced the area of deposited collagen 
I to 0.03% and 0.6% in the rapid and accelerated modes respectively (Figure 




Figure 10 Optical evaluation of extracellular interference with collagen 
deposition. (a) C-proteinase inhibitor PCP56 reduced collagen I area/cell to 40% 
(control, p = 0.003) and 82% (TGF1, p = 0.047) in rapid mode, and 52% (control, p 
= 0.036) and 43% (TGF1, p = 0.018) in accelerated mode. No significant effects 
with FSY002. (b) Area of fibronectin/cell was reduced to 46% (control, p = 0.037) and 
36% (TGF1, p = 0.005) by PCP56 in rapid mode, and increased to 123% (TGF1, p 
= 0.004) in accelerated mode. (c) Cell numbers with PCP56 were slightly reduced to 
91% (control, p = 0.012) and 94% (TGF1, p = 0.006) in rapid mode, and 92% 
control, p = 0.035) and 83% (TGF1, p =0.002) in accelerated mode. (d-e) 
Biochemical analysis of deposited collagen I reduction by PCP56 in the rapid mode 
of collagen deposition. (d) Collagen I deposited on the cell layer is visibly reduced 
with PCP56 treatment. (e) Pepsin digested procollagen I is increased in the medium 
fraction of cell culture with PCP56 treatment. Data are expressed as mean ± s.d., 




Figure 11 Optical evaluation of extracellular interference with collagen 
stabilisation. (a) BAPN did not change area of collagen I/ cell, but reduced area of 
fibronectin/cell to 62% (DxS, p = 0.006) and 69% (Fc, p = 0.012) in the absence of 
TGF1 (b) without affecting cell numbers (c). BAPN effects were evident after SDS 
PAGE (d-e), showing -cross-links reduced to 24% and 33% (TGF1), and 62% and 
32% (TGF1) in the rapid (f) and accelerated mode (g), respectively. Each lane 
represents pooled triplicates and data is represented as fold change in comparison 
with respective control. *p < 0.05 versus respective controls. Data are expressed as 
mean ± s.d., calculated from triplicates and as fold changes over respective controls. 
Figure from [10]. 
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Figure 12 Optical evaluation of MMP1 activity on deposited collagen I and 
fibronectin. Collagen I was deposited on the cell layer under DxS/Fc crowding as a 
substrate prior to MMP1 digestion. (a) MMP1 similarly reduced collagen I area to 
0.03% (DxS, p = 0.003) and 0.6% (Fc, p = 0.0004). (b) The area of Fn was reduced 
to 2% (DxS, p = 0.008) and 18% (Fc, p = 0.02). (c) MMP1 digestion detached cells 
and significantly reduced cell numbers in the rapid mode to 1.6% (p = 0.0004) 
whereas cell numbers in the accelerated mode were relatively unaffected. *p < 0.05 
versus respective controls. Data were expressed as mean ± s.d., calculated from 




Figure 13 Biochemical validation of intracellular collagen biosynthesis 
inhibitors by silver stained SDS PAGE. The (a, c, e, g) rapid (DxS) and  (b, d, f) 
accelerated (Fc) modes of collagen deposition were treated with  (a-b) 1 μM TSA, (c-
d) 10 mM PDCA, (e-f) 8 μM CPX and (g) 10 nM M29c. Inhibitor treatment at the 
epigenetic, post-transcriptional and post-translational level resulted in a decrease of 
deposited collagen in the absence and presence of TGF1. Each lane represents 
pooled triplicates. Figure from supplementary data of [10]. 
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Figure 14 Biochemical validation of extracellular collagen biosynthesis 
inhibitors by silver stained SDS PAGE. ECM was deposited using the (a) rapid 
(DxS) and (b) accelerated (Fc) modes prior to addition of 50 μg per 24-well of 
exogenous MMP1. MMP1 digested the collagen I deposited in both modes. Each 
lane represents pooled triplicates. Figure from supplementary data of [10]. 
 
 
Table 3 Sumary of antifibrotic effects assessed by the Scar-in-a-Jar 
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3.4 Discussion   
 
Fibrosis has remained an unconquered therapeutic bastion. An important 
obstacle in the development of antifibrotics has been the lack of a 
comprehensive in vitro screening system, although all relevant biochemical 
steps of collagen matrix formation have been known for quite some time. The 
confounding factor of cell culture in standard aqueous media is its 
characteristic dissimilarity to the native crowded state of tissue. Thus, the 
enzymatic conversion of procollagen to collagen by C-proteinase is too tardy 
as to allow the deposition of a substantial collagen matrix in a useful time 
window [2, 70]. This already forecasts that the effects of C-proteinase 
inhibitors would be invisible under routine culture conditions, and IC50 cell-free 
assays used to test inhibitors of isolated enzymes and their corresponding 
substrates will not be an accurate physiological reflection of the inhibitors 
efficacy in vivo. Thus, the risk of obtaining inconclusive results in experimental 
animals is considerable.  
 
This is where the Scar-in-a-Jar takes monolayer culture to an unparalleled 
pathophysiological level. Collagen deposition and cross-linking is substantially 
increased in vitro, with the option of two deposition modes. The rapid 
deposition mode produces granular collagen I aggregates within 48 hours [2, 
70], and a neutral combination of Ficoll 70 and 400 was found to produce 
collagen I with a reticular deposition pattern within 6 days. Thus amount, 
velocity and morphology of collagen deposition can be controlled depending 
on the macromolecules used. The accelerated mode (Fc) with its longer 
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culture time also produces collagen with a larger extent of cross-linking. 
Optical quantitation of two-dimensional images of three-dimensional granular 
aggregates as produced in the rapid mode can result in under-reporting of 
deposited collagen, but less so with a reticular network (accelerated mode). 
 
The rapid mode (DxS), however, allows for a faster data output due to a 
shorter culture time. TGF1, a notorious culprit in fibrotic conditions [122], 
resulted in an additional 1.5 to 2-fold increase of collagen deposition in 
comparison with controls under both modes of crowding. TGF1 has 
pleiotropic effects; it slows down matrix turnover by reducing MMP1 
expression, up-regulates lysyl oxidase activity and increases the presence of 
tissue inhibitors of MMPs [123]. These effects are only apparent with a 
deposited matrix, underlining the importance of this novel screening system.  
 
We compared our system with a FP model [12] that consists of TGF1-
exposed hyperconfluent fibroblasts that form cell sheets. Destructive methods 
were employed to quantify hydroxyproline without the option to correct for cell 
number or total protein content. A modified version has been recently used by 
a Pfizer team [13] to assess C-proteinase inhibitors. In comparison, the FP 
models contained considerably less deposited collagen after 8 and 18 days 
than crowded subconfluent cultures, even in the absence of TGF1 for the 
latter. Of note, the ECM of FP contained collagen V, which is usually absent 
from fibrotic tissue [124]. Thus, the ECM lacking collagen V under the rapid 
deposition mode would emulate a fibrotic matrix more closely. Also, there was 
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a 1.5 to 2-fold increase of lysyl oxidase-mediated cross-links under crowded 
conditions in contrast to FP models, and this improvement of enzyme activity 
in vitro will facilitate the screening of another important therapeutic target in 
anti-fibrosis research. 
 
Known and novel antifibrotic compounds were evaluated (Table 3) and an 
overall close correlation between optical and biochemical quantitation 
methods were found. However, the Scar-in-a-Jar provides the option for 
simultaneous evaluation of other antigens and cell enumeration within the 
same well. This proved crucial in the case of TSA, which is known to be anti-
proliferative in cancer cells [125, 126], as it also inhibited fibroblast growth. 
After correction for cell numbers, our findings agree excellently with earlier 
work based on metabolic labelling and immunoprecipitation of collagen I 
which showed that TSA suppressed TGF1-induced fibrogenesis in vitro 
[127]. This and other current work suggests a new role for this compound 
class in fibrosis treatment [128].  
 
We demonstrate the first instance of evaluating prolyl hydroxylase inhibitors 
under conditions of full matrix deposition. PDCA causes intracellular 
procollagen retention [69], and related compounds are currently under 
evaluation for their cross-inhibitory effects on HIF-1- prolyl hydroxylase 
[129]. Its dual potential of inhibiting fibrosis while inducing angiogenesis was 
recently demonstrated in transgenic zebrafish [11]. CPX is FDA-approved for 
the topical treatment of cutaneous mycoses (Batrafen®). As an iron chelator it 
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was predicted to interfere with prolyl hydroxylases [117]. We show here 
profound effects of CPX on the deposition of collagen, a novel example for 
indication discovery and an interesting antifibrotic off-label potential for this 
compound.  
 
Targeting enzymes responsible for the proteolytic trimming of procollagen is 
another feasible antifibrotic strategy. To interfere with this step, a variety of 
procollagen C-proteinase/bone morphogenic protein-1 inhibitors have been 
designed [13, 130, 131]. Procollagen cleavage by C-proteinase is enhanced 
under macromolecular crowding in vitro.  This feature enables the Scar-in-a-
Jar to assess C-proteinase inhibitors in a native enzyme/substrate system 
under pathological scarring conditions, which was not possible prior to this 
set-up. The novel sulfonamide inhibitor PCP56 demonstrated efficacy in 
excellent agreement with an earlier report [13]. Biochemically, we noted the 
re-appearance of collagen I in the culture medium under PCP56 during 
crowding, proving the exclusion of the non-converted procollagen from matrix 
building. Another PCP inhibitor (FSY002) did not work in our system although 
an IC50 was obtained with purified procollagen C-proteinase [130] (data not 
shown). 
 
Based on observations in heritable connective tissue disorders [132], 
interfering with collagen cross-linking has been proposed to make scar tissue 
more susceptible to degradation [133, 134]. Biochemical analysis clearly 
demonstrated the reduction of collagen cross-linking by BAPN in the rapid 
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mode (DxS) and when added daily after the first 48 hours in the accelerated 
mode (Fc), but overall collagen I amount was not reduced (Figure 7d-g). 
Similarly, optical analysis did not detect a reduction of collagen I matrix in 
either deposition mode, but was unable to differentiate and quantify cross-
linked collagen. These results correspond with earlier findings that BAPN 
neither affects the amount of collagen synthesized nor the hydroxyproline 
distribution between cell layer and medium [135]. However, a contrasting 
report found reduced collagen matrix in hyperconfluent cells (under non-
crowded conditions) under TGF1/BAPN treatment for three days [12]. 
Collagen cross-link reduction does not necessarily translate to reduced 
pericellular collagen. Perhaps under crowded conditions, increased collagen 
turnover due to reduced collagen cross-links might not be perceptible within 
this time frame due to enhanced collagen deposition. 
 
MMP1 has an important remodelling role in fibrosis. In contrast to other 
evaluation methods of MMP1 activity involving synthetic fluorescent 
substrates or zymography [136, 137], we applied recombinant MMP1 to cell 
layers with a complex ECM bioassembled via both deposition modes (DxS 
and Fc). Efficient matrix degradation by MMP1 caused cell detachment of 
varying degrees and precluded application of the cytometry feature of our 
discovery tool. Optical quantitation of the total post-depositional reduction of 
collagen and fibronectin per well was performed instead. This represents an 
important step to evaluate MMP1 formulations designed to locally modulate 
tissue composition in a wound healing setting.  
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Current reports have implicated the miR29 family at the gene expression 
level, to play a role in ECM gene regulation of COL1A1, COL1A2, COL3A1, 
COL4A1, COL4A2, COL5A2, SPARC and FBN1 in tumour cells (Sengupta et 
al., 2008) and miR29b in particular, regulates COL1A1, COL1A2, COL3A1 
and FBN1 in cardiac fibrosis (van Rooij et al., 2008). Mcl-1 protein regulation 
by miR29c resulted in apoptosis induction (Mott et al., 2007) and recently, the 
miR29 family was also found to reduce p85 and CDC42 mRNA levels in 
HeLa cells (Park et al., 2009).  The Scar-in-a-Jar demonstrates for the first 
time, evidence for a potential antifibrotic effect of mimic miR29c at the protein 
level and confirms the mathematical prediction of rna22. This tool has the 
advantage of a read-out system focused on the net reduction of collagen I, 
regardless of multiple targets being affected simultaneously. For example, 
miR29c may regulate other key genes involved in the collagen biosynthetic 
cascade other than targeting collagen I, such as hsp47 [138] , which was 




In conclusion, the Scar-in-a-Jar offers a novel pathophysiologically relevant 
screening and evaluation tool for antifibrotic lead compounds interfering with 
different key points of the collagen biosynthesis pathway, ranging from the 
epigenetic to the extracellular level.  
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3.6 Beyond the Scar-in-a-Jar 
 
The pleiotropic effects of macromolecular crowding on the ECM in cell culture 
are continuously being studied and our recent results [114] are included as an 
addition to this chapter. 
 
3.6.1 Materials and Methods 
 
3.6.1.1 Procollagen C-proteinase immunoblotting 
 
Fibroblasts were seeded on 24-well plates at 50,000/well in 10% FBS, 5% 
CO2 at 37
oC. After 16 hours, the medium was changed to DMEM containing 
0.5 % FBS, 100 μM of L-ascorbic acid phosphate magnesium salt -hydrate 
with or without 500 kDa dextran sulphate (DxS) at 100 μg mL-1 or a mixture of 
37.5 mg mL-1 Ficoll 70 with 25 mg mL-1 Ficoll 400 (Fc) and cultured for 2 days 
and 6 days.  
 
Medium samples were harvested at these time points and resolved using the 
NuPAGE tris-acetate 3-8% gradient pre-cast gel system (Invitrogen, Grand 
Island, NY), and transferred to a nitrocellulose membrane. Immuno-detection 
was carried-out in tris-buffered saline Tween-20 pH 7.6 (50 mM Tris-base 150 
mM NaCl/0.05% Tween 20) with 5% non-fat milk. Mouse anti-human 
procollagen type I C-propeptide was used at 5 μg/mL, mouse anti-hsp47 was 
used at 1 μg/mL, and a secondary goat anti-mouse conjugated to HRP 
(Thermo Scientific, Rockford, IL) was used at 1/1000 dilution for 1 hour. The 
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signal was detected by chemiluminescence and captured with a VersaDoc 
Imaging System model 5000.  
 
3.6.1.2 FITC-labeling of collagen 
 
A 3 mg/mL collagen I solution (Koken Co., Tokyo, Japan) was microdialyzed 
[140] against 1x PBS for 24 hours at 4oC. The collagen I in solution was then 
labelled using a Fluoreporter FITC-labeling kit (Invitrogen, Grand Island, NY) 
according to the manufacturers instructions, then microdialyzed against 0.02 
M acetic acid for 24 hours at 4oC. The labeled collagen I was quantified by 
SDS PAGE and silver staining (as mentioned earlier in chapter 3). 
 
3.6.1.3 The effect of macromolecular crowding on collagen assembly in 
vitro 
 
20,000 WI-38 fibroblasts were seeded in 8-well Lab-Tek chamber slides and 
allowed to to attach overnight in DMEM with 10% FBS, 5% CO2 at 37
oC. 
Medium was then changed to serum-free DMEM with 100 μM of L-ascorbic 
acid phosphate magnesium salt -hydrate with or without a mixture of 37.5 
mg mL-1 Ficoll 70 with 25 mg mL-1 Ficoll 400, and 50 μg mL-1 FITC-labeled 
collagen I. This was incubated for 24 hours at 5% CO2 and 37
oC before 
samples were fixed with 10% buffered formalin and mounted with 




3.6.1.4 The effect of macromolecular crowding on cell-free collagen 
supramolecular assembly 
 
3 mg/mL collagen I (Koken Co. Tokyo, Japan) was mixed with 2x, 5x or 10x 
PBS to obtain concentrations of 1.5 mg/mL, 2.4 mg/mL and 2.7 mL collagen I 
respectively. Turbidity of the solution was quantified using a 
spectrophotometer at 313 nm every minute for 75 mins. Macromolecules, 
comprising 37.5 mg mL-1 Ficoll 70 with 25 mg mL-1 Ficoll 400 (Fc), were 
incorporated to the 2.7 mg/mL and 1.5 mg/mL collagen I solutions. Turbidity of 
the solutions was measured every 30 seconds for 30 minutes, and every 15 
minutes for 180 minutes, respectively. 
 
3.6.2 Results and Discussion 
 
It is interesting to observe the faster rate of procollagen C-propeptide 
cleavage by procollagen C-proteinase with both modes of crowding in 
comparison with controls (Figure 15), but it is even more interesting to 
observe the effect that macromolecules have on collagen I supramolecular 
assembly.  
 
This effect was first studied using FITC-labeled collagen I in the presence of 
cells. After 24 hours incubation with the addition of macromolecules, there 
was increased fibrillar collagen I self-assembled on the cell layer (Figure 16a) 
compared with uncrowded controls. Investigation of macromolecular crowding 
on non-enzymatic collagen I supramolecular assembly was taken a step 




Figure 15 Enhanced cleavage of the procollagen C-propeptide under 
macromolecular crowding. Medium samples (pooled triplicates) were resolved on 
a 3-8% gradient NuPAGE gel, transferred to a nitrocellulose membrane and 
immunoblotted for the intact procollagen C-propeptide. Uncrowded (UC) samples 
were compared with crowded (DxS, Fc) samples after 2 days and 6 days of culture. 
At day 2, both DxS and Fc samples enhanced cleavage of the C-propeptide from 
pro, intact type I procollagen heterotrimers, to leave C3, three disulphide-bonded 
free C-propeptide chains.  At day 6, uncrowded controls appear to have a 
heterogenous mix of incompletely cleaved procollagen populations, but addition of 
DxS and Fc to culture medium appear to have enhanced propeptide cleavage such 
that mostly C3 was detected. Pro, two pro- chains disulphide bonded to a free C-
propeptide chain; Pro, one pro- chain disulphide bonded to a free C-propeptide 
chain. Figure from [114]. 
 
supramolecular assembly eventually occurs in the absence of crowding 
(Figure 16b and c top panel), however, thicker and longer fibrils (Figure 16b) 
were obtained at a faster rate  (Figure 16b) in the presence of 
macromolecules as shown with phase contrast microscopy. Turbidity 
measurements also gave an indication that more collagen I aggregates form 




Figure 16 Enhanced collagen I supramolecular assembly under 
macromolecular crowding. (a) Collagen I was labeled with FITC and 50 μg/mL was 
added to fibroblast cell culture and allowed to incubate for 24 hours. Addition of Fc 
enhanced fibrillar collagen I self-assembly on the cell layer, which did not occur in the 
absence of cells. 100x magnification. (b-c) Spontaneous collagen I supramolecular 
assembly under cell-free conditions. b) Phase-contrast microscopy images of  fibril 
formation in a 1.5 mg/mL collagen I solution at various time points. Collagen I fibrils 
formed faster and thicker with addition of Fc. 200x magnification. c) A turbidity assay 
was performed to quantify the rate of collagen I fibril formation. Absorbance was read 
at 313 nm using a spectrophotometer. Top panel: The turbidity read-out system is 
dependent on the concentration of the collagen I solution. This was performed under 
non-crowded conditions. Middle panel: Addition of Fc to 2.4 mg/mL collagen I 
solution resulted in an increased rate and amount of fibril formation. Triplicates of 
each condition were measured. Bottom panel: Addition of Fc to 1.5 mg/mL collagen I 
solution also caused an increase in the rate and amount of fibril formation, and 





Hence from these findings, we have shown that the enhanced rate of collagen 
I deposition in the presence of macromolecular crowding is manifested due to 
a culmination of increased 1) enzymatic conversion to insoluble collagen I 









Peri-implantational fibrosis:  









This chapter explains the challenge of peri-implantational fibrosis faced by 
tissue engineers when developing biomaterials. Besides inhibiting collagen 
capsule formation by directly targeting collagen I deposition, improvement of 
vascularization within an implant can serve to better support integration with 
host tissue for an indirect antifibrotic effect. 
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4.1 Biomaterials in tissue engineering 
 
There is a constant introduction of new biomaterials to the field of tissue 
engineering for the purpose of medical and non-medical uses. Unfortunately, 
while we have learned from rejection and failure of biomaterials due to 
infection, inflammation and toxicological effects, such complications still do 
occur [141].  The main problem faced by a biomaterial and the current 
bottleneck in tissue engineering, is the formation of an avascular collagen 
capsule surrounding the implant, causing implantable devices and materials 
to lose functionality over time [7]. Limited lifespan and functionality in vivo is a 
critical issue caused by tissue- or blood- device interface interactions, normal 
homeostatic response to implantations, or even to a lack of biocompatibility 
[20, 142, 143]. These problems stem from the bodys end stage reaction to 
inflammation and wound healing, known as the foreign body response (FBR).  
 
4.2 Foreign body response  
Upon implantation, a tissue-device interface is created, and non-specific 
adsorption of proteins from blood and tissue fluid immediately occurs [7].The 
degree of the FBR is dependent on several properties of the 
biomaterial/device such as sterility, surface chemistry, composition, and 
degradation rate [142]. The process of implantation itself triggers a cascade of 
inflammatory and wound healing responses comprising an initial acute phase 
and a subsequent chronic phase.   
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Fluid, protein exudation and neutrophilic reaction are characteristics of the 
acute phase, which can last from hours up to days. This is responsible for the 
cleaning of the wound and formation of the provisional matrix. Cytokines and 
growth factors are released and leukocytes infiltrate the injury site. Monocytes 
are attracted to the site as well, and differentiate into macrophages [144]. 
Persistent inflammatory stimuli due to the biomaterial/device lead to chronic 
inflammation. Monocytes, macrophages and lymphocytes are present in this 
phase, and proliferation of blood vessels and connective tissue occurs to 
reconstruct the affected area and to protect the body from the foreign object 
[145, 146]. The granulation tissue is eventually replaced by an ECM which 
acts as a scaffold and a modulator of differentiation and repair [147]. The final 
stage of the FBR is to surround the biomaterial/implant with an avascular, 
collagenous fibrous capsule that is around 50 – 200 μm thick [7, 148], which 
prevents the biomaterial/implant from interacting with the surrounding tissue 
(Figure 17).  
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Figure 17 Foreign body reaction to and avascular capsule formation around an 
implanted biomaterial. (a) The illustrated foreign body reaction is the normal 
reaction of higher organisms to an implanted synthetic material. (Figure adapted from 
[7]). (b) mPCL/Col nanofiber scaffolds were implanted in the corpus cavernosa of 
male New Zealand White rabbits for 1 month. H&E stain revealed thick granulation 
tissue was observed in the tissue surrounding the biomaterial (40x magnification). 
The solid black arrow indicates the location of the scaffold, and the hollow arrows 
point out encapsulation of the scaffold due to the foreign body response. Figure 




4.3 Biocompatibility  
Biocompatibility is defined as the ability of a material to perform with an 
appropriate host response in a specific application [142, 143, 148]. This is 
further divided into a) biosafety, when there is an appropriate systemic and 
local host response with the absence of cytotoxicity, mutagenesis and 
carcinogenesis, and b) biofunctionality, when the material is able to perform 
the task it was designed for [150].   
 
However, there is a great difficulty in testing the biocompatibility of a material 
in vitro, as mimicking inflammation and the FBR in cell culture is currently not 
possible. Testing for non-specific protein adsorption (biofouling), cell 
attachment and proliferation are only indirect indicators of biocompatibility. 
Recent developments in high-throughput technologies to assess 
biocompatibility (for an extensive review, see [151]) include identification of 
key regulatory elements associated with the fibrotic response so as to 
optimise a tissue engineering strategy [10, 152], understanding the 
environment which will be tissue engineered [153] and defining a gene 
signature [154]. The aim is to rapidly, and systematically study the molecular 
environment as a whole. For example, Dinnes et al. [155] searched for protein 
expression changes in monocyte derived macrophages (MDM) cultured on 
different material surfaces using 2-dimensional electrophoresis and matrix-
assisted laser desorption ionisation (MALDI)-time of flight. MDMs are key 
inflammatory cells in the host response to biomaterials, and the protein 
expression changes were assessed with the aim to discover the cellular 
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mechanisms involved in the inflammation response. Recently, liquid 
chromatography MALDI has also been applied to investigate the mechanism 
of monocyte-material interactions [156]. This demonstrates a move towards 
creating “smart” or active biomaterials, which requires modification in the way 
compatibility is assessed. Unfortunately, a FBR is still a common barrier for 
normal function of medical devices, such as biosensors [157, 158], drug 
delivery systems [143, 159], eye implants [160], etc.   
 
Modifications to biomaterials and implants are constantly being done to 
improve its biocompatibility, such as hydrogel coatings of glucose sensors in 
order to prevent biofouling and to improve functionality [161] and the 
development of poly-N-acetyl glucosamine nanofibers to improve wound 
healing by enhancing cell migration and angiogenesis [162]. Drug delivery by 
biomaterials has also been introduced as another facet to reduce 
inflammation and fibrosis. Encapsulation of thymoquinone in poly (lactide-co-
glycolide) nanoparticles inhibited NF-B activation and reduced production of 
angiogenic factors in vitro [163]. Dexamethasone-loaded poly(lactic-co-
glycolic) acid (PLGA) microsphere/poly(vinyl alcohol) (PVA) microspheres 
were also designed as a glucose biosensor coating to reduce inflammation 
[5]. Chow et al. [164] used a block copolymer with anti-inflammatory 
molecules as a copolymer-therapeutic hybrid for a drug delivery system. 
Besides addressing the issue of biocompatibility, vascularization of a 
biomaterial is another major concern of tissue engineers. 
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4.4 Vascularization of biomaterials  
In order to fabricate complex and functional tissues or to maintain the 
functionality of glucose sensors for example, it is necessary to develop 
biomaterials that can be sufficiently vascularized. The process of 
angiogenesis involves a complex interaction between endothelial cells (ECs), 
the interstitial ECM, and the neighbouring mural cell types via direct 
interaction or via various growth factors [165, 166]. VEGF activates ECs in the 
initial phase of angiogenesis, causing them to proliferate and secrete various 
proteases such as matrix metalloproteinases to degrade the basement 
membrane and ECM. This allows the ECs to migrate and extend sprouts to 
build tubular structures. Stabilization of these nascent vessels requires the 
recruitment of mural cells such as smooth muscle cells and mesenchymal 
stem cells, which differentiate into pericytes and deposit new ECM proteins for 
the basal lamina [167, 168]. 
 
The design of pro-angiogenic biomaterials thus requires the integration of 
cellular, biochemical, and biophysical cues in order to achieve angiogenesis  
in vitro, and angiogenesis and vascularization in vivo. Incorporation of VEGF 
is one of the most popular growth factors employed in biomaterial 
vascularization strategies [169-174]. Localized delivery of VEGF through 
biomaterials helps to improve tissue-specific targeting, low systemic exposure 
and prolonged exposure times [175]. However, human clinical trials have 
demonstrated that therapeutic effects of this growth factor are only achieved 
at extremely high doses, and sustained release is necessary for the 
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stabilization of vessels [176].  High dosing may result in side effects such as 
hypotension, retinopathy, or progression of malignant tumours [176-178]. 
Moon et al. developed a biomimetic polyethylene glycol hydrogel with integrin-
binding and MMP-sensitive sites to allow formation of a vascular network with 
human umbilical vein endothelial cells (HUVECs). These hydrogels were 
further linked with VEGF to promote neovascularization in vivo [169]. Besides 
entrapment of VEGF in extracellular matrices [179], several groups have 
turned to more stable anchoring of VEGF to natural substrates modified with 
Heparin for increased binding [180, 181] and a more sustained release of 
VEGF [182]. Other than extracellular matrices, synthetic substrates such as 
titanium were also functionalized with VEGF. This modified surface 
demonstrated improved attachment and proliferation of endothelial cells, as 
well as to direct mesenchymal stem cell differentiation into endothelial cells 
[183].  
 
In addition to considering delivery of VEGF in biomaterials, an extra layer of 
complexity is the evidence that the effects of angiogenic growth factors are 
highly dependent on the timing of their expression and their concentration 
gradients [184]. In an elegant study by Ozawa et al., 2004, a 
microenvironmental VEGF threshold appears to exist, that separates the 
growth of capillary-like vessels from that of hemangiomas, with no stable 
intermediate abnormal structures. This threshold specifically refers to the 
localized extracellular environment of each cell, and not a group of cells 
Additionally, they found that the phenotype of mural cells (-/+ -SMA) 
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associated with the normal/abnormal vessels corresponded with the type of 
capillaries formed [184]. Besides spatial considerations, temporal presentation 
of VEGF plays an important role as well. In an in vivo study by Silva et al., 
they found that high levels of VEGF at early time points resulted in a 
significant increase in EC sprouting compared with a constant or gradually 
increasing VEGF dose over time, which instead led to less sprouting [185].  
 
Heparin and heparan sulfate are linear polysaccharides composed of 
repeating glucosamine-hexuronic acid disaccharide units [186]. Heparan 
sulfate chains are found attached to core proteins in proteoglycans on cell 
surfaces and within the ECM of nearly all mammalian cells and tissues [187]. 
The seminal observations that basic fibroblast growth factor (bFGF or FGF-2) 
required binding to cell-surface heparan sulfate proteoglycan and it cell-
surface receptor for biological activity [188, 189], initiated recognition that 
growth factors (GFs) and their activity are regulated by forming complexes 
with pericellular matrix molecules and ECM (reviewed in [190]). VEGF is also 
such a growth factor, and all VEGF-A isoforms (VEGF121, 145, 165, 189, 206) except 
VEGF121 bind to heparan sulfate or to heparin [191, 192]. Heparin augments 
interactions of VEGF165 with VEGF receptor 2 (VEGFR2) [193] and binds to 
VEGF receptor 1 [194]. Platelet-derived growth factor BB and phosporylation 
of its receptor and downstream signalling are also modulated by heparin 
[195]. Interestingly, because heparin can interact with both receptors and 
ligands, it facilitates their approximation [196] and alters their conformation 
[197]. On this note, it is possible to imagine that since such ECM-GF 
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complexes markedly enhance GF activity, this might drive down the GF dose 
required for therapy to the nano- or even picogram level. Hence, solid-state 
presentation of GFs in a nanospace may improve signal transduction 
pathways to stimulate cell proliferation for tissue regeneration and healing, 
thus prompting the rationale of incorporating heparin into their biomaterials 
[171, 180, 198-200]. 
 
So far, only a few groups have attempted to directly address both problems of 
fibrosis and vascularization in the design of their biomaterials. Previous works 
include the incorporation of VEGF in addition to dexamethasone in PLGA 
microsphere/PVA hydrogel composites, and biomimetic hydrogels with 
proangiogenic properties [169, 201]. We intend to develop a self-vascularizing 
and antifibrotic biomaterial by delivering small molecule compounds that 











Development of an antifibrotic and self-vascularizing  












This chapter describes the dual benefits of prolyl hydroxylase inhibitors and 
their employment in the development of a biomaterial. Design considerations 
for the biomaterial includes the choice of materials and pore sizes, localized 
drug delivery modes, and biocompatibility. Antifibrotic and angiogenic 




5.1.1 Prolyl hydroxylase 
 
5.1.1.1 The role of prolyl 4- hydroxylase in collagen biosynthesis  
 
Prolyl 4-hydroxylase (proline, 2-oxoglutarate 4-dioxygenase, EC 1.14.11.2) 
(P4H), is responsible for the hydroxylation of prolyl residues in X-Pro-Gly 
sequences to form 4-hydroxylproline [202]. The reaction mechanism requires 
cosubstrates Fe2+, 2-oxoglutarate, molecular O2 and ascorbate. These 4-
hydroxyprolyl residues are essential for the folding and stabilization of newly 
synthesized procollagen polypeptide chains into triple-helical molecules at 
physiological temperature. Therefore, this property makes P4H an interesting 
target for pharmacologic modulation as a means to treat fibrotic disorders 
characterized by uncontrolled overproduction of collagen [203] as exemplified 
by the use of 2,4-pyridinedicarboxylic acid (2,4-PDCA) in Figure 18.  
 
5.1.1.2 The role of prolyl hydroxylase in angiogenesis 
 
Hypoxia inducible factor-1 (HIF-1) is tightly regulated. Under conditions of 
normoxia, newly synthesized HIF-1 are continuously earmarked for rapid 
degradation by hydroxylation of two prolyl residues within the oxygen-
dependent degradation domain, by HIF-prolyl hydroxylases (HIF-PH) [204]. 
Additionally, hydroxylation of a single asparaginyl residue by asparaginyl 





Figure 18 Inhibition of prolyl 4-hydroxylase by 2,4-pyridinedicarboxylic acid. 
2,4-PDCA enters the intracisternal compartment and attaches to the co-substrate-
binding site of prolyl 4-hydroxylase as a non-utilizable 2-oxoglutarate analogue. This 
prevents the enzyme from from progressing through its catalytic cycle before the 
formation of the ferryl ion, which is the reactive species effecting prolyl hydroxylation. 
The prevention of collagen hydroxylation leads to intracisternal accumulation of 
denatured non-helical collagenous molecules, which are transferred to lysosomes for 
degradation. Figure adapted from [69]. 
 
 
Since these enzymes require molecular oxygen for catalytic activity, their 
function is inhibited in hypoxia [206]. As a result of this, under-hydroxylated 
HIF-1 is not degraded and promotes transcription of over 50 target genes 
including VEGF and its receptor, FLT-1 [207]. Hence, inhibiting HIF-PH will 
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stabilise HIF-1 even at conditions of normoxia and trigger an angiogenic 
cascade (Figure 19).  
 
 
Figure 19 Regulation of the HIF-1 transcription factor. Under normoxic 
conditions, the oxygen-dependent degradation domain of HIF-1 is modified by a 
HIF-prolyl hydroxylase triggering its recognition by von Hippel-Lindau tumour 
suppressor gene (pVHL), a component of a ubiquitin ligase complex that tags the 
subunit for degradation by the proteosome. Similarly, an asparaginyl hydroxylase 
modifies HIF-1, blocking its interaction with p300. Hypoxia blocks both prolyl 
hydroxylation and aspraginyl hydroxylation, allowing HIF-1 to accumulate and bind 
to p300, promoting the transcriptioin of downstream HIF-1 target genes. Figure 
adapted from [208]. 
 
5.1.2 Prolyl hydroxylase inhibitors 
 
Instead of conventionally delivering VEGF through a biomaterial, we have 
opted for a pharmacologic approach using prolyl hydroxylase inhibitors (PHi). 
The dual benefit to inhibit collagen synthesis as well as to stimulate 
angiogenesis with the use of one compound is appealing. With the 
extraordinary expense associated with growth factor therapy, the economic 
advantage of using small, stable molecules that will survive biomaterial 
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production/processing is also attractive. We will be incorporating three prolyl 
hydroxylase inhibitors, 2,4-pyridine dicarboxylic acid (PDCA), ciclopirox 
olamine (CPX) and hydralazine (HDZ) (Figure 20) into a biomaterial. PDCA 
and CPX were previously demonstrated in chapter 3 to possess antifibrotic 
potential with the Scar-in-a-Jar [10], by reducing the amount of collagen I 
deposited (Figure 9). Both the antifibrotic and angiogenic properties of PDCA 
and HDZ were previously demonstrated in vitro through fibroblast and 




Figure 20 Prolyl hydroxylase inhibitors. 2,4-pyridine dicarboxylic acid is a 2-
oxoglutarate analogue, and competitively and reversibly binds with prolyl hydroxylase 
to interfere with its activity. The mode of action of this inhibitor is specific for this 
enzyme. Ciclopirox olamine (CPX) and hydalazine (HDZ) are both Fe2+ chelators, 
and they disrupt the coordination of 2-oxoglutarate (OGT) with the ferryl ion thus 
preventing hydroxylation of prolines.  
 
Immunoblotting of fibroblast lysates confirmed the presence of HIF-1 in 
hypoxic but not normoxic cells, and there was a dose-dependent stabilisation 
of HIF-1 in fibroblasts with both HDZ and PDCA (Figure 21a). Enzyme-linked 
immunosorbent assay (ELISA) confirmed stimulation of VEGF secretion as 
well (Figure 21b). In untreated cocultures of fibroblasts and human umbilical 
vein endothelial cells (HUVECs), HUVECs formed clusters in comparison with 
positive VEGF controls and certain concentrations of PDCA and HDZ with 
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resulted in the formation of capillary-like structures (CLS) (Figure 21c). PHi 
and VEGF also induced ectopic subintestinal vessels (SIV) in zebrafish 
embryos (Figure 22). 
 
 
Figure 21 Confirmation of angiogenic effects of prolyl hydroxylase inhibitors in 
human cell culture. (a) Western blots of fibroblast cell lysates show accumulation of 
HIF-1 in comparison to -actin under HDZ and PDCA in a dose dependent manner; 
normoxia (Nor) and hypoxia (Hyp). (b) PHi induced an increase of VEGF secretion of 
fibroblasts as demonstrated by ELISA. (c) PHi induced capillary-like structures (CLS) 
in co-cultures of fibroblasts and HUVECs, compared with clusters obtained in 





Figure 22 Angiogenic potential of PHi demonstrated in transgenic (Fli-1:EGFP) 
zebrafish embryos at 72 hpf immersed in the angiogenic compounds. (a) 
Controls: live fluorescence microscopy demonstrates the normal phenotype of EGFP 
expressing intersegmental blood vessels (ISV) and subintestinal vessel plexus (SIV) 
with a smooth basket-like structure with 5-6 arcades (asterisks) (b) VEGF: 
development of knobbly projections from the SIV. (c, d) HDZ treatment: ectopic 
vessels extrude ventrally as spikes from the SIV basket (arrows) and branching 
vessels create new intersection points (arrowheads). (e, f and g) PDCA treatment: 
development of an enlarged SIV basket (>7 arcades, asterisks) and spikes (arrows) 
(h) There is a dose-dependent effect of HDZ and PDCA on zebrafish embryo 
angiogenesis with maximal effect observed at 1 mM HDZ and 30 mM PDCA. Mean 
percentages were computed from three independent experiments. Asterisks: 






5.1.3 Incorporation of PHi into a biomaterial 
 
Electrospinning provides a means to fabricate macro- to nanoscale fibers 
comparable with proteins in the ECM. These types of scaffolds are often 
desirable in tissue engineering due to their high surface area-to-volume ratios 
and porosity, together with topographical features to encourage cell adhesion, 
surface migration and proliferation [209]. Additionally, the versatility of 
electrospinning allows for customization of surface chemistry, fabrication of 
aligned structures and incorporation of bioactive molecules [210, 211].  
 
Unfortunately, with such densely deposited fibers, the resultant pores have 
small dimensions that prohibit cell penetration within the scaffold. This 
characteristic may limit the development and application of electrospun fibers 
as scaffolds, especially in the tissue engineering of three-dimensional (3D) 
tissues and organs. Ekaputra et al. has developed cell permeable electrospun 
scaffolds by coelectrospinning micron-sized medical grade poly(-
caprolactone)/collagen (mPCL/Col) while codepositing HeprasilTM, a synthetic 
ECM based on chemically modified hyaluronic acid (HA) and chemically 
modified heparin [212] that was developed for 3D cell culture and tissue 
engineering (Figure 23a) [213]. The resultant composite biomaterial consisted 
of a hybrid fibrous mPCL/Col mesh, with entrapped regions of HA hydrogel 




Figure 23 Development of the mPCL/Col-Hep composite biomaterial. (a) A two-
capillary electrospinning-electrospraying system was used to produce Heprasil 
hydrogels embedded in mPCL/Col meshes. Figure adapted from [214]. (b) 
Composition of mPCL/Col-Hep biomaterial. (b-A) The SEM micrograph illustrates the 
micron-sized fibers in the mesh. (b-B) The biomaterial was immunostained for 
collagen I, and a higher magnification image (b-C) demonstrates the uniform 
distribution of collagen I on/within the microfibers. (b-D) FITC was mixed with 
Heprasil in order to observe the distibution of the hydrogel within the mesh. A higher 
magnification image (B-E) shows pockets of Heprasil trapped in the mPCL/Col 
micofiber network. Figure from Ekaputra, unpublished data. 
 
 
The aim in this chapter is to adopt the mPCL/Col-Hep material and adapt it to 
deliver prolyl hydroxylase inhibitors, thus producing an antifibrotic and 
angiogenic biomaterial (Figure 24a and b). In response to PHi diffusing out of 
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either the hydrogels or the microfibers (2 modes of drug delivery), we expect 
fibroblasts to reduce their deposition of collagen I, as well as increase their 
production of VEGF. This VEGF can either be bound to a receptor of an 
endothelial cell to trigger an angiogenic cascade, or it may be bound to 
heparin which is cross-linked within the HA hydrogel. The heparin-bound 
VEGF may be used by another endothelial cell at a later time point. As 
previously reported, the HA hydrogel can be used as a controlled release 
vehicle for growth factors such as VEGF and fibroblast growth factor [171, 
215]. Hence in our biomaterial design, we intend the device/implant to be a 
self-replenishing VEGF reservoir to sustain angiogenic signalling (Figure 24c). 
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Figure 24 Design of a self-vascularizing and antifibrotic biomaterial. (a) A two-
capillary electrospinning-electrospraying system was used to produce Heprasil 
hydrogels embedded in mPCL/Col meshes. PHi were either incorporated within the 
electrosprayed hydrogel fraction as a mode 1 of delivery, or within the PCL/Col 
microfibers as mode 2 of delivery. (b) A schematic of the composite biomaterial. (c) 
In response to released PHi from the hydrogel for example, fibroblasts will increase 
their VEGF production, which will either be used by an endothelial cell, or become 
bound to heparin cross-linked within the hydrogel to create a VEGF reservoir.  
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5.2 Materials and Methods 
 
 
5.2.1 Fabrication of mPCL/Col-Hep materials 
 
mPCL/Col-Hep materials were fabricated as previously described [214]. The 
electrospinning solution was made by preparing a 20% w/v solution of 
mPCL/Col (80/20 by mass) in 1,1,1,3,3,3-fluoro 2-propanol (HFIP). This 
solution was then electrospun using a 19-G blunt needle connected to a 
negative 9 kV power supply. Material feed rate and needle-to-mandrel 
distance of 4.0 mL/hr and 6 cm was used, respectively. This process 
produced mPCL/Col fibers with a diameter of 1-2 μm. HeprasilTM was 
prepared as per manufacturers protocol. Lyophilized Heprasil and its thiol 
reactive cross-linking agent, Extralink were reconstituted into recommended 
working concentrations and were mixed together to form the hydrogel solution 
with a 4:1 volume ratio of Heprasil to Extralink. For electrospraying purposes, 
the solution was further mixed in a 1:1 volume ratio with 3% gelatin solution to 
modify its viscosity and gelling time. The hydrogel solution was electrosprayed 
within 30 minutes after mixing the components, before extensive cross-linking 
occurred. Electrospraying was carried out by connecting a 21-G blunt needle 
to a positive 7 kV power supply with a hydrogel solution feed rate of 1.6 mL/hr 
and a distance of 6cm. The mPCL/Col-Hep material was made by 
simultaneous collection of electrospun mPCL/Col and electrosprayed Heprasil 
solution on a collection mandrel connected to a ground rotating at a speed of 
100 RPM.  The collected mesh was stored in a dessicator overnight to allow 
complete evaporation of organic solvent. PHi were incorporated into either the 
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Heprasil hydrogel component (mode 1) or mPCL/Col solution (mode 2) prior 
to electrospraying/electrospinning to produce a final concentration of 1 mM, 
10 mM and 50 mM PDCA, 0.8 μM, 8 μM and 40 μM CPX, and 10 μM, 100 μM 
and 500 μM HDZ. For in vivo studies, human recombinant VEGF from 
Millipore (Temecula, CA) was incorporated into the Heprasil hydrogel 
component to deliver 100 ng VEGF per disc.  
 
5.2.2 Drug release profiles 
 
8 mm diameter mPCL/Col-Hep discs delivering PHi either via the hydrogel 
component (mode 1) or the mPCL/Col microfibers (mode 2) were sterilized, 
immersed in 1 mL PBS and incubated at 37oC. PBS was completely 
withdrawn and replaced at 1, 2, 3, 4, 5, and 6 hours, and 1, 2, 3, 4, 7, 14 and 
28 days. Samples were stored at -80oC prior to quantitation. Quantitation of 
PHi was carried out by spectrophotemetry at absorption wavelengths of 276 
nm, 305 nm and 262 nm for PDCA, CPX and HDZ, respectively. Standard 
curves were prepared (Figure A1, appendix section) and mPCL/Col-Hep discs 
without any drugs were used as blanking controls to take background 
absorbance from leachable or degradation products into account. Triplicates 
of each condition were measured. 
 
5.2.3 In vitro cell attachment and infiltration 
 
Cell culture. Prior to cell seeding, discs were biopsy punched out of 
mPCL/Col-Hep materials with PHi incorporated into either the hydrogel 
component (mode 1) or the mPCL/Col microfibers (mode 2), using an 8 mm 
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biopsy punch to obtain 0.5 cm2 circular scaffolds. Discs were sterilized with 
ethanol immersion and UV irradiation, placed in 100 μm cell strainers (BD, 
Franklin Lakes, NJ) in 60 mm Petri dishes and conditioned with medium 
overnight (Figure 25b). 300,000 IMR-90 fibroblasts,  were seeded on the discs 
and cultured for 14 days, with a medium change after 7 days. 
 
 
Figure 25 Cell culture set-up. (a) VEGF reservoir analysis. Fibroblasts were 
seeded in hanging cell culture inserts and mPCL/Col-Hep discs were trapped at the 
base of the hanging insert. Fibroblasts were cultured in medium with various 
concentrations of PDCA, CPX and HDZ for 14 days before being transferred to 
microcentrifuge tubes for VEGF release. (b) Fibroblast attachment and infiltration 
study, and fibroblast and HUVEC coculture study. mPCL/Col-Hep discs (-/+ PHi) 
were place in cell strainers, and 4 strainers (quadriplicates) were placed in one 60 
mm Petri dish. Discs were conditioned with culture media overnight before cells were 
seeded on each disc and culture for 14 days. 
 
 
Scanning electron microscopy (SEM). Morphology and attachment of cells on 
the scaffolds after 14 days in culure, was imaged using a SEM. Discs with 
cells were fixed in 2.5% glutaraldehyde for 4 hours at room temperature, then 
dehydrated by an increasing ethanol gradient, followed by drying in a vacuum 
chamber. For electron microscopy, the discs were mounted on viewing stubs 
and gold sputtered using a glow discharge sputter coater. A Phillips XL30FEG 
electron microscope was used for viewing.  
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Hematoxylin and Eosin stain. After 14 days in culture, the discs with cells 
were fixed in 10% formalin for 4 hours at room temperature, rinsed with PBS 
and embedded in Tissue-Tek optimal cutting temperature (OCT) compound 
(Sakura, Torrance, CA). Sample cross-sections of 10 μm thickness were cut 
using a Leica cryo-microtome, and fixed onto Superfrost Plus microscope 
slides (Thermo Scientific, Waltham, MA). Sections were stained with 
hematoxylin and eosin (H&E) in order to visualize cells in the mPCL/Col-Hep 
discs delivering PHi. Cell nuclei stained bluish-purple, while cytoplasm and 
ECM stain pink. 
 
5.2.4 Bioactivity of incorporated PHi 
 
Cell culture. 300,000 IMR-90 fibroblasts were cultured on mPCL/Col-Hep 
discs in the set-up illustrated in figure 37b, for 14 days in DMEM containing 
10% FBS and 100 μM L-ascorbic acid phosphate magnesium salt -hydrate. 
1 mL of medium was withdrawn and replenished at day 2, 7 and 14 time 
points, and harvested medium was stored at -80oC. Culture medium was 
changed after 7 days.  
 
VEGF ELISA. VEGF secreted by the IMR-90 fibroblasts in response to PHi 
released from mPCL/Col-Hep delivered by both modes, was quantified using 
a VEGF Enzyme-Linked Immunosorbent Assay kit (R&D Systems, 
Minneapolis, MN) according to the manufacturers instructions.  
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Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Samples were resolved under non-reducing conditions using in-house 5% 
resolving/3% stacking polyacrylamide gels on a Mini-Protean 3 as outlined in 
Raghunath et al. [93]. Protein standards used were the Precision Plus Dual 
Colour and Prestained Broad Range, and collagen type I standards. Protein 
bands were stained with the SilverQuest™ kit (Invitrogen, Grand Island, NY) 
according to the manufacturers protocol. Densitometric analysis of wet gels 
was performed on both collagen 1(I)- and 2(I)-bands with a GS-800™ 
Calibrated Densitometer and Quantity One v4.5.2 image analysis software.  
 
IMR-90 fibroblast and HUVEC coculture. A total cell number of 300,000 cells, 
comprising a mixture of IMR-90 fibroblasts and HUVECs in a 5:1 ratio were 
simultaneously seeded on sterilized and conditioned 8 mm mPCL/Col-Hep 
discs delivering PHi in both modes. Positive controls were cultured in EGM-2 
medium (Lonza, Basel, Switzerland) supplemented with 5 ng/mL human 
recombinant VEGF (Millipore, Temecula, CA). Cells seeded on control 
materials (no PHi) and materials delivering PHi, were cultured in EGM-2 
medium without VEGF and FGF-2 supplements, for 14 days. Medium was 
changed after 7 days. 
 
von Willebrand factor (vWF) immunostain. Cocultures on mPCL/Col Hep -/+ 
PHi were harvested after 14 days, and whole discs were fixed in ice-cold 
methanol for 10 minutes in -20oC before blocking with 10% goat serum in PBS 
for 30 minutes. This was followed by incubation with polyclonal rabbit anti-
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vWF (Dako Cytomation, Glostrup, Denmark) at 1:500 dilution for 90 minutes 
at room temperature then 30 minutes with a 1:400 dilution of AlexaFluor 594 
goat anti-rabbit secondary antibody and 0.5 μg/mL 4,6-diamidino-2-
phenylindole,dihydrochloride (DAPI) (all from Molecular Probes, Eugene, OR). 
Whole discs with fluorescent immunostains were imaged using an Olympus 
FV500 laser scanning confocal microscope. 
 
5.2.5 VEGF reservoir analysis 
 
Prior to cell seeding, discs were biopsy punched out of plain mPCL/Col-Hep 
materials without PHi, using an 8 mm biopsy punch to obtain 0.5 cm2 circular 
scaffolds. Discs were sterilized with ethanol immersion and UV irradiation. 
These discs were then trapped below the cell culture inserts within close 
proximity to the cells, but separation is maintained (Figure 25a). 8,500 IMR-90 
fibroblasts were seeded in Millicell Hanging Cell Culture inserts for 24-well 
plates, from Millipore (Temecula, CA), with 1 μm pore sizes. Fibroblasts were 
allowed to attach overnight in DMEM with 10% FBS, 5% CO2 at 37
oC. Medium 
was then changed to DMEM containing 10% FBS with 1 mM, 10 mM and 10 
mM PDCA, 0.8 μM, 8 μM and 40 μM CPX, and 10 μM, 100 μM and 500 μM 
HDZ, and cells were cultured for 14 days in this set-up. Medium was changed 
after 7 days. After 14 days, discs were transferred to microcentrifuge tubes 
under sterile conditions, and 300 μL release buffer comprising PBS, 1% BSA, 
1 mM EDTA, 10 μg/mL heparin (sodium salt from porcine mucosa) from 
Sigma-Aldrich (St. Louis, MO) was added. Release buffer was completely 
withdrawn and replaced after 1, 7 and 14 days, and stored at -80oC. A 48-
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hour hyaluronidase (Sigma-Aldrich, St Louis, MO) digest in release buffer was 
performed on mPCL/Col-Hep discs after 14 days, and the samples were 
stored at -80oC. VEGF released from the materials was quantified using a 
VEGF ELISA kit from R&D Systems (Minneapolis, MN) according to the 
manufacturers instructions.  
 
5.2.6 Rat renal pouch model 
 
This study conforms to the Guide for the Care and Use of Laboratory Animals 
published by the U.S. National Institutes of Health (NIH publication no. 85-23, 
revised 1996). The National University of Singapore—Instituitional Animal 
Care and Use Committee, approved the experimental protocol. Male SPF 
Sprague Dawley rats (300 - 350 g) were used for our experiments. 2 rats were 
used per sample group (i.e. 4 renal pouches). All surgical procedures were 
performed using aseptic techniques as mentioned previously [216]. 
Anesthesia was induced and maintained in animals by isoflurane (2%) 
inhalation, and intraperitoneal injection of ketamine:xylazine (3.75 mg/100g : 
0.1 mg/100g). Carprofen (0.5 mg/100g) was subcutaneously (SC) 
administered preoperatively as an analgesic. A midlaparotomy was 
performed, followed by displacement of the bowel and mild retraction of the 
kidney. Blunt preparation of the retroperitoneal fossa was performed and a 
pouch was created between the retrorenal fat and the psoas muscle. A total of 
8 groups were tested; controls, VEGF controls, 1 mM PDCA, 10 mM PDCA, 
0.8 μM CPX, 8 μM  CPX, 10 μM  HDZ and 100 μM  HDZ. 8 mm diameter 
mPCL/Col-Hep discs delivering PHi or 100 ng VEGF per disc in the hydrogel 
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component were implanted in the retrorenal pouch. We did not use suture 
material in the implantation process. Finally, the bowel was repositioned and 
the abdomen was closed in two layers. Carprofen (0.5 mg/100g) was 
administered 5 days postoperatively as an analgesic, and the rats were 
euthanized after 7 days. 
5.2.7 Histological analysis 
 
After 7 days of implantation, explants were harvested and fixed in 4% 
paraformaldehyde (PFA) for 3 hours in 4oC. Tissues were embedded in OCT 
compound and sectioned to 10 μm thickness. Hematoxylin and eosin staining 
was carried out in order to qualitatively assess the degree of cell infiltration 
and fibrosis. 
 
5.2.8 DiI perfusion assay 
 
Functional blood vessels were assessed by the cardiac perfusion of DiI 
(Molecular Probes, Eugene, OR) as previously described [217]. Briefly, a DiI 
stock solution of 6 mg/mL was prepared in 100% ethanol and diluted 50 times 
in a diluent comprising a 1:4 ratio of PBS and 5% glucose solution to obtain a 
concentration of 120 μg/mL, just prior to cardiac perfusion. Post-euthanasia of 
the rat after 7 days, the heart cavity was exposed and a catheter was inserted 
into the left ventricle and the right atrium was punctured. 2 mL of PBS was 
injected into the left ventricle, and a sign of good perfusion was confirmed with 
bleeding from the right atrium, then this was followed by injection of 10 mL DiI 
solution. Implants and the surrounding tissue were immediately excised and 
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fixed in 4% PFA. Explants were embedded in OCT compound and sectioned 
to 100 μm thickness. Sections were viewed using a Nikon TE600 
fluorescence microscope. 
5.2.9 RECA-1 immunohistochemistry and cell scoring 
 
Immunohistochemistry. Explants were sectioned to 10 μm thickness and 
tissue sections were blocked with 10% goat serum in PBS. 
Immunohistochemical staining was performed using the primary antibody 
against rat endothelial cell antigen 1 (RECA-1), a ubiquitous marker of rat 
endothelial cells at a 1:50 dilution (Hycult Biotechnology, Uden, The 
Netherlands). The sections were then incubated with the secondary antibody 
AlexaFluor 595 goat anti-mouse at a 1:400 dilution, and nuclei were stained 
with DAPI (all from Molecular Probes, Eugene, OR). Sections were viewed 
using a Nikon TE600 fluorescence microscope. 
 
Cell scoring. The Cell Scoring Module of the Metamorph® Imaging System 
software (Molecular Devices, Sunnyvale, CA) was used to identify and 
quantify the number of cells positively expressing RECA-1. At least 5 random 
fields at 100x magnification were selected in each section. Parameters were 
empirically determined, and nuclei were defined as a centroid with a minimum 
length of 5 μm and maximum of 15 μm, and fluorescent intensity 10 gray 
levels above the local background. The positive marker (RECA-1) was defined 
as an object with a minimum of 8 μm and maximum of 20 μm in length, with a 
fluorescent intensity 1300 gray levels above the local background. A nucleus 
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was scored positive if it overlapped with the positive marker of defined 
parameters. 
5.2.10 Statistical analysis 
 
Data are presented as means ± s.d. and as fold changes of relevant controls. 
The statistical significance between groups was determined by students t-test 
using a two-tailed distribution with unequal variance. An effect was considered 
significant when 1.0 did not belong to the 95% confidence interval of the 
sample in comparison with controls (*p value <0.05). 
5.2.11 Materials 
 
All reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO) unless otherwise stated. IMR-90 fibroblasts were obtained from the 
American Tissue Culture Collection (CCL-186, VA, USA), and HUVECs were 
purchased from Lonza (C2519A, Basel, Switzerland). Cell culture reagents 
were all purchased from Gibco (Grand Island, NY) unless otherwise stated. 
Cell culture plasticware (CELLSTAR®) was obtained from Greiner Bio-One 
(Frickenhausen, Germany) unless otherwise stated. Medical grade PCL was 
purchased from Absorbable Polymers International (Birmingham, AL). Medical 
grade type I bovine collagen was purchased from Symatese Biomateriaux 
(Chaponost, France). Heprasil was purchase from Glycoson Biosystems (Salt 
Lake City, UT). For electrospinning, a high voltage generator was purchased 
from Gamma High Voltage Research (Ormond Beach, FL). Syringe pumps 
were purchased from KD Scientific (Holliston, MA). 
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5.3 Results  
 
5.3.1 Mode of PHi delivery affects release profile 
 
Varying concentrations of PHi were incorporated into either the hyaluronic 
acid hydrogel component or the mPCL/Col fibers during electrospinning as 
means for localised delivery. In mode 1, all inhibitors were burst-released from 
the biomaterial, with a dose-dependent response (Figure 26). All 
concentrations of PDCA reached a plateau after 14 days (Figure 26a), CPX 
after 7 days (Figure 26b), and HDZ after 4 days (Figure 26c). In mode 2, 
biomaterials delivering 50 mM PDCA demonstrated a burst-release that 
reached a plateau after 2 hours. Low and steadily increasing release profiles 
in a dose-dependent manner were obtained from mPCL/Col-Hep delivering 1 
mM and 10 mM PDCA (Figure 27a). Biomaterials incorporating 0.8 μM and 8 
μM CPX had detectable drug release after 5 and 6 hours, respectively (Figure 
27b). HDZ release was detected from 10 μM and 500 μM HDZ after 5 hours, 
and the 10 μM HDZ biomaterials appeared to reach a plateau after one day 
(Figure 27c). mPCL/Col-Hep delivering 500 μM HDZ continued to produce a 
slow and steadily increasing release profile up to 28 days (Figure 27c). Drug 




Figure 26 Drug release profile of PHi delivered via mode 1. (a-c) The diffusion of 
varying concentrations of PDCA, CPX and HDZ from the biomaterial was quantified 
using spectrophotometry. (a) There was a dose-dependent burst release of PDCA, 
which reached a plateau after 14 days. (b) There was a dose-dependent burst 
release of CPX, which reached a plateau after 7 days. (c) There was a dose-
dependent burst release of HDZ, which reached a plateau after 4 days. 
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Figure 27 Drug release profile of PHi delivered via mode 2. The release of drugs 
from mPCL/Col-Hep biomaterials delivering varying concentrations of PDCA, CPX 
and HDZ from the biomaterial was quantified using spectrophotometry. (a) There was 
a dose-dependent burst release of PDCA from mPCL/Col-Hep delivering 50 mM 
PDCA, which reached a plateau after 2 hours. Slow and steady release profiles in a 
dose-dependent manner were obtained from biomaterials delivering both 10 mM and 
1 mM PDCA. (b) Drug release from biomaterials delivering 0.8 μM and 8 μM CPX 
was only quantified after 5 and 6 hours, respectively, followed by a plateau. There 
was no quantifiable drug released from mPCL/Col-Hep delivering 40 μM CPX. (c) 
Released HDZ was detected after 5 hours for both sets of biomaterials delivering 10 
μM and 500 μM  HDZ. Release from the 10 μM HDZ samples reached a plateau after 
1 day, but 500 μM HDZ samples continued to produce a slow and steady release 
profile of HDZ up to 28 days. There was no quantifiable drug released from 
mPCL/Col-Hep delivering 100 μM HDZ. 
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5.3.2 Incorporation of PHi does not affect ability of mPCL/Col-Hep 
to support cell attachment and infiltration  
 
IMR-90 fibroblasts were used to assess the ability of cells to attach, proliferate 
and infiltrate into the PCL/Col-Hep biomaterials with PHi delivered by both 
modes. Cell attachment was not impeded by localised delivery of PHi, 
regardless of the concentrations or type of PHi used (Figure 28a and 29a). A 
confluent cell layer was obtained after 14 days in culture (data not shown) 
indicating that proliferation was not affected. Haematoxylin and eosin (H&E) 
stains of biomaterial transverse sections demonstrated that cellular infiltration 
after 14 days was not impaired by the localised delivery of PHi, compared with 
controls that had no PHi incorporated (Figure 28b and 29b). Fibroblasts were 
able to migrate into the biomaterial, without any negative effects caused by 
the incorporated PHi.  
 
5.3.3 PHi released from the biomaterials were bioactive 
 
IMR-90 fibroblasts were used to assess both the angiogenic and antifibrotic 
properties of the biomaterials in vitro. Fibroblasts were seeded on the 
biomaterials and cultured for 14 days (Figure 25b). Medium was harvested at 
day 2, 7 and 14 to enable quantitation of VEGF and collagen I secreted by the 
fibroblasts (Figure 30 and 31). In mode 1, results from the VEGF ELISA 
demonstrated that there was no significant difference in VEGF levels at day 2 
compared with controls. At day 7, 50 mM PDCA and 0.8 μM CPX caused a 
56% (p = 0.003) and 63% (p = 0.02) increase in VEGF secretion compared 
with controls, respectively. A longer-term significant effect of 50 mM PDCA, 
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0.8 μM and 40 μM CPX on increased fibroblast VEGF secretion was observed 
at day 14 (Figure 30a). 
 
Figure 28 Attachment, proliferation and infiltration of fibroblasts on mPCL/Col-
Hep with PHi delivered via mode 1. (a) Scanning electron micrographs illustrate 
that localised delivery of PHi did not inhibit cell attachment and proliferation. 5000x 
magnification, scale bar represents 5 μm. (b) Histological analysis of cell infiltration 
into the biomaterial using haematoxylin and eosin (H&E). Localised delivery of 
varying concentrations of PHi did not interfere with cell infiltration into the mPCL/Col-
Hep biomaterial. Red arrowheads indicate location of selected nuclei. 400x 




Figure 29 Attachment, proliferation and infiltration of fibroblasts on mPCL/Col-
Hep with PHi delivered via mode 2. (a) Scanning electron micrographs illustrate 
tha localised delivery of PHi did not inhibit cell attachment and proliferation. 5000x 
magnification, scale bar represent 5 μm. (b) Histological analysis of cell infiltration 
into the biomaterial. Localised delivery of varying concentrations of PHi did not 
interfere with cell infiltration into the mPCL/Col-Hep biomaterial. Red arrowheads 
indicate location of selected nuclei. 400x magnification, scale bar represents 40 μm. 
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HDZ did not cause any significant effect on VEGF secretion at any of the time 
points (Figure 30b). In mode 2, there were no significant increases in secreted 
VEGF by fibroblasts on PHi biomaterials compared with controls at day 2 
(Figure 31a). Biomaterials with 1 mM PDCA and 0.8 μM CPX incorporated 
caused a noticeable difference in VEGF production at day 7, which increased 
it by 30% (p = 0.02) and 47% (p = 0.008) respectively compared with controls 
(Figure 31a). By day 14, incorporated 1 mM PDCA and 8 μM CPX in the 
biomaterials continued to have a stimulatory effect on fibroblasts by 212% (p 
= 3 x 10-5) and 421% (p = 0.04) increased VEGF secretion in comparison with 
controls, respectively (Figure 31a). 
 
For mode 1 of PHi delivery, densitometry of the collagen I -bands indicated 
that 0.8 μM CPX reduced collagen I secretion by 19.8% at day 2. Most PHi 
took effect by day 7, when all inhibitors except for 40 μM CPX caused a 
reduction in collagen I secretion. 1 mM, 10 mM and 50 mM PDCA decreased 
collagen I secretion by 19%, 23% and 35% respectively. 0.8 μM and 8 μM 
CPX reduced collagen I secretion by 20% and 29%.  Only 50 mM PDCA and 
8 μM CPX had a prolonged effect on day 14, reducing collagen I secretion by 
54% and 19% respectively (Figure 30c). HDZ caused a slight reduction of 
collagen I secretion at day 2, with 10 μM and 100 μM concentrations. These 
caused a 18% and 14% reduction respectively. There was no noticeable 
effect day 7, and only 500 μM CPX caused a 46% reduction in collagen I 
secretion at day 14 (Figure 30d). For mode 2 of PHi delivery, collagen I 
secretion continued to be affected by PHi incorporated within the microfibers 
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at day 7. 1 mM (19%), 10 mM (25%) and 50 mM (25%) PDCA, 0.8 μM (36%), 
and 8 μM (21%) CPX, together with 10 μM (29%), 100 μM (32%) and 500 μM 
(53%) HDZ all caused a reduction of collagen I in comparison with controls 
(Figure 31b). Only 10 mM PDCA (18%) and 10 μM HDZ (31%) appeared to 
have a prolonged suppressive effect on collagen I secretion by day 14 (Figure 
31b). 
 
5.3.4 Incorporated PHi induced capillary-like structure formation  
 
In vitro cocultures of IMR-90 fibroblasts and HUVECs on mPCL/Col-Hep 
delivering various concentrations of the three PHi, were used to assess the 
angiogenic potential of the biomaterials. For both modes of PHi delivery, 
capillary-like structures (CLS) were obtained for positive controls that 
comprised cells cultured on mPCL/Col-Hep in full HUVEC medium 
supplemented with an additional 5 ng/mL VEGF (Figure 32 and 33). Negative 
controls and mPCL/Col-Hep + PHi samples were all cultured in basal HUVEC 
medium (-VEGF, -FGF). In mode 1, CLS formed on mPCL/Col-Hep 
biomaterials delivering 10 mM PDCA, 0.8 μM and 8 μM CPX, and 10 μM, 100 
μM and 500 μM HDZ (Figure 32). In mode 2, CLS were obtained on 
biomaterials delivering 1 mM and 50 mM PDCA, as well as 0.8 μM CPX and 









Figure 30 Assessment of angiogenic and antifibrotic bioactivity of delivered 
PHi via mode 1. (a-b) VEGF secreted from fibroblasts seeded on the biomaterial into 
the culture medium, was quantified by ELISA at day 2, 7 and 14 time points. Control 
refers to the biomaterial without PHi incorporated into the hydrogel. Biomaterials with 
HDZ were tested in a separate study. (c-d) Secreted collagen from fibroblasts 
seeded on the biomaterial was quantified from culture medium at day 2, 7 and 14 
time points. Samples were pepsin digested and pooled triplicates were resolved by 
SDS-PAGE, followed by silver staining and densitometry. Data is presented as fold 
change of collagen I in comparison with controls. (a) VEGF ELISA quantitation 
showed that there was no significant difference between samples compared with 
controls at day 2. At day 7, 50 mM PDCA and 0.8 μM CPX caused a significant 
increase of VEGF production compared with controls.  Only biomaterials delivering 
50 mM PDCA, 0.8 μM and 40 μM CPX had a significant effect on VEGF levels after 
14 days. (*p < 0.05) (b) None of the HDZ concentrations made any significant 
differences in VEGF levels compared with controls, at any time point. (*p < 0.05) (c) 
Biochemical analysis of collagen I secreted in the culture medium indicated that at 
day 2, only 0.8 μM CPX caused a reduction of secreted collagen I compared with 
controls. All PDCA samples, together with 0.8 μM and 8 μM CPX samples showed a 
reduction of collagen I, compared with controls at day 7. At day 14, 50 mM PDCA 
and 8 μM CPX caused a reduction in collagen I secretion compared with controls. (d) 
Only 100 μM and 500 μM HDZ appeared to cause a reduction in collagen I secretion 




Figure 31 Assessment of angiogenic and antifibrotic bioactivity of delivered 
PHi via mode 2. (a) Fibroblasts were cultured on the biomaterials, and ELISA was 
used to quantify the VEGF secreted at day 2, 7 and 14 of culture. Control refers to 
the biomaterial without PHi incorporated into the mPCL/Col microfibers. There were 
no significant differences between controls and samples at day 2. At day 7, 1 mM 
PDCA and 0.8 μM CPX incorporated into the biomaterial caused a significant 
increase of 30% (p = 0.02) and 47% (p = 0.008) in secreted VEGF compared with 
controls, respectively. 1 mM PDCA, and 8 μM CPX had a longer term stimulatory 
effect with an increase of 212% (p = 3 x 10-5) and 421% (p = 0.04) of VEGF levels at 
day 14, compared with controls respectively. Incorporated HDZ did not cause a 
significant increase in VEGF secretion at any time points compared with controls. (*p 
< 0.05) (b) Secreted collagen I from fibroblasts cultured on the biomaterials was 
harvested from the medium at 2, 7 and 14 days, pepsin digested and pooled 
triplicates were resolved by SDS-PAGE. The gels were silver stained and 
densitometry was performed to find fold changes of collagen I in samples compared 
with controls. At day 2, 1 mM and 10 mM PDCA, all concentrations of CPX and 100 
μM and 500 μM of HDZ reduced collagen I secretion by at least 20%. All 
concentrations of the three inhibitors except for 40 μM CPX caused a reduction in 
secreted collagen I at day 7. After 14 days, 10 mM PDCA and 10 μM HDZ reduced 





Figure 32 Capillary-like structure formation of cocultures on mPCL/Col-Hep 
delivering PHi via mode 1. IMR-90 fibroblasts and HUVECs were simultaneously 
seeded and cocultured on mPCL/Col-Hep delivering varying concentrations of the 
three PHi, for 14 days. Basal HUVEC medium was used to culture the negative 
controls, and the positive controls were cultured in full HUVEC medium 
supplemented with an additional 5 ng/mL VEGF. All cells on mPCL/Col-Hep + PHi 
were cultured in basal medium. Cells were immunostained for von Willebrand factor 
(vWF) (red) and the nuclei were stained with DAPI (blue), and the cocultures on the 
materials were viewed using confocal microscopy. A confluent layer of cells was 
obtained as demonstrated in the images for both negative and positive controls. Cell 
nuclei have been omitted in the rest of the images for the sake of clarity. Capillary-
like structures (CLS) comprising endothelial cells had formed on the biomaterial 
under positive control conditions. CLS were also obtained on biomaterials delivering 
10 mM PDCA, 0.8 μM and 8 μM CPX, and 10 μM, 100 μM and 500 μM HDZ. 100x 




Figure 33 Capillary-like structure formation of cocultures on mPCL/Col-Hep 
delivering PHi via mode 2. IMR-90 fibroblasts and HUVECs were simultaneously 
seeded and cocultured for 14 days on the biomaterials delivering varying 
concentrations of the three PHi. Basal HUVEC medium was used to culture cells on 
the negative controls and the mPCL/Col-Hep +PHi biomaterials. Positive controls 
were cultured in full HUVEC medium supplemented with an additional 5 ng/mL 
VEGF. Cells were immunostained for vWF (red) and the nuclei were stained with 
DAPI (blue). A confluent layer of cells was obtained as illustrated in both negative 
and positive controls, and cell nuclei have been omitted in the rest of the images for 
the sake of clarity. Capillary-like structures (CLS) had formed on positive controls, as 
well as 1 mM and 50 mM PDCA, 0.8 μM CPX and 100 μM HDZ. 100x magnification, 
scale bar represents 200 μm. 
 
 
5.3.3 De novo synthesised VEGF was stored and released by 
mPCL/Col-Hep  
 
In order to study the VEGF reservoir property of the biomaterial, IMR-90 
fibroblasts seeded in hanging cell culture inserts were induced to increase 
secretion of VEGF by adding various concentrations of PDCA, CPX and HDZ 
to the culture medium. mPCL/Col-Hep discs were trapped under the culture 
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inserts in close proximity to the cells (Figure 25a). VEGF loading was carried 
out for 14 days, and its release was assessed at 1, 7 and 14 days after 
loading. A hyaluronidase digest was then performed on the discs to release 
any remaining VEGF. In the absence of cells, there was a dose dependent 
trend of exogenous VEGF storage and release by the biomaterial loaded 
under conditions of 5 ng/mL and 10 ng/mL VEGF. 110 pg (p = 0.0002) and 
263 pg (p = 0.01) of VEGF was released after 1 day, 15 pg (p = 0.02) and 25 
pg (p = 0.01) after 7 days, and there was no detectable VEGF released after 
14 days. 6 pg (p = 0.02) and 11 pg (p = 0.003) was released after the 
hyaluronidase digest, from discs loaded with 5 ng/mL and 10 ng/mL VEGF, 
respectively (Figure 34).  
 
Fibroblasts produced a basal amount of VEGF without PHi stimulation, but 
storage and release of this from the mPCL/Col-Hep biomaterial was low in 
comparison with addition of PHi to the culture medium. At day 1 of release, 
500 μM HDZ resulted in the greatest amount of de novo VEGF (39 pg, p = 
0.01), followed by 8 μM (23 pg VEGF, p = 0.002) and 40 μM (21 pg VEGF, p 
= 0.04) CPX. Only 500 μM HDZ conditions produced a significant difference in 
comparison with controls on day 7 with a release of 5 pg (p = 0.003) of VEGF 
(Figure 34), with no detectable VEGF at day 14.  
 
The final hyaluronidase digest indicated a significant increase in stored de 
novo VEGF between conditions of 500 μM HDZ, 8 μM and 40 μM CPX 
compared with controls, and 13 pg (p = 0.05), 9 pg (p = 0.05) and 4 pg (p = 
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0.003) of VEGF were released respectively (Figure 34). These results are 
similar to those obtained from mPCL/Col-Hep biomaterials loaded with 
exogenously added VEGF in the absence of cells (Figure 34). 
 
The total amount of VEGF stored under the various conditions was calculated 
based on the release data. In the absence of cells, 131 pg (p = 0.0007) and 
309 pg (p = 0.02) of VEGF was stored in discs cultured with 5 ng/mL and 10 
ng/mL VEGF added to the medium (Figure 35). Only under culture conditions 
with 8 μM and 40 μM CPX, together with 500 μM HDZ, was there a significant 
increase in VEGF storage of 33 pg (p= 0.005), 27 pg (p = 0.04) and 55 pg (p 
= 0.003) VEGF respectively, in comparison with fibroblast controls (Figure 
35). 
 
5.3.4 Implantation of materials in the rat renal pouch model 
 
From the in vitro data, biomaterials with mode 1 of PHi delivery within the 
hydrogels were selected for the first round of in vivo testing. The two lowest 
concentrations of each inhibitor were assessed, and negative controls were 
plain mPCL/Col-Hep biomaterials without any inhibitors, while positive 
controls were mPCL/Col-Hep biomaterials that delivered approximately 100 
ng VEGF per mPCL/Col-Hep disc via the hydrogels. 
 
8 mm diameter mPCL/Col-Hep biomaterials (Figure 36a) were implanted in 
the renal pouches of Sprague Dawley rats (Figure 36b-c). There were no rat 
mortalities before the scheduled euthanasia. There were no visible signs of 
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Figure 34 Release of exogenous and de novo VEGF from the mPCL/Col-Hep 
biomaterial. In the absence of fibroblasts, there was a dose dependent release of 
exogenously added VEGF at day 1, 7 and after the hyaluronidase digest for 5 ng/mL and 10 
ng/mL VEGF conditions. Data of VEGF release at day 14 was omitted because there was no 
detectable VEGF. Treatment of fibroblasts with PHi resulted in increased VEGF storage and 
thus its release in comparison with controls, although fibroblasts did produce a basal amount 
of VEGF in the absence of any PHi. 500 μM HDZ caused a significant release of VEGF by 
day 1, followed by 8 μM and 40 μM of CPX in comparison with controls. Only 500 μM HDZ 
samples produced a significant release of VEGF after 7 days in comparison with controls. 
VEGF was not detected at day 14 of the release study.  Following the hyaluronidase digest, 
quantified VEGF at this point was more than day 7 in almost all samples, except for 1 mM 
PDCA. 500 μM HDZ, 8 μM and 40 μM CPX released significantly more VEGF compared with 
controls. The amount of VEGF released from the biomaterial discs in 500 μM HDZ conditions 
was similar to discs exposed to 10 ng/mL VEGF conditions in the absence of cells. 
Biomaterial discs in 8 μM CPX conditions had 3 pg more VEGF than discs exposed to 5 






Figure 35 Storage of exogenous and de novo VEGF in the mPCL/Col-Hep 
biomaterial. VEGF released in the mPCL/Col-Hep discs under various conditions 
were added up from the day 1, 7 and hyaluronidase digest time points to obtain an 
estimate of VEGF storage. In the absence of cells, culture of discs with 5 ng/mL 
VEGF and 10 ng/mL VEGF resulted in 131 pg (p = 0.0007) and 309 pg (p = 0.02) of 
VEGF being stored, respectively. In the presence of fibroblasts with PHi treatment, 8 
μM and 40 μM CPX, and 500 μM HDZ had a significant storage of 33 pg (p = 0.005), 
27 pg (p = 0.04) and 55 pg (p = 0.003) VEGF respectively, in comparison with 
fibroblast controls. (*p value < 0.05 in comparison with respective controls) 
 
infection and inflammation, or foreign body reactions after 1 week of 
biomaterial implantation in the renal pouch (Figure 36d and f). Explanted 
mPCL/Col-Hep discs had not degraded and maintained their size and shape, 
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and blood vessels were observed in the periphery of the biomaterials, 
particularly for mPCL/Col-Hep delivering CPX and HDZ (Figure 37).  
 
5.3.5 Peri-implantational fibrosis  
 
Foreign body reaction to the implants and fibrous capsule formation around 
the biomaterials were investigated using hematoxylin and eosin (H&E) stains 
of explant cross-sections. After 7 days, cell infiltration was obvious throughout 
the biomaterial, regardless of the drugs they were delivering (Figure 38). 
Fibrous encapsulation of the biomaterials was not prominent, even in controls 
which were not delivering PHi (Figure 38). 
 
Figure 36 Implantation of biomaterials in the rat renal pouch model. (a) 8 mm 
diameter discs were biopsy punched from the mPCL/Col-Hep biomaterials. (b) The 
renal pouch is a pocket of fat located below the kidneys and biomaterials were 
implanted in pouches created by blunt dissection of the tissue (c). (d) At the selected 
time point for sacrifice, observations of the implant site revealed no infection and 
minimal inflammation and mPCL/Col-Hep discs had not dislodged from the site of 
implantation (e). (f) The biomaterials were excised with the surrounding tissue for 
further analysis. Black arrows indicate the location of a renal pouch, and red arrows 
indicate the location of the biomaterial. 
 
 120 
5.3.6 Functional blood vessel infiltration into implants  
 
1,1-dioctadecyl-3,3,3-tetramethylindocarbocyanine perchlorate (DiI), a 
lipophilic carbocyanine dye that incorporates into endothelial cell membranes 
upon contact, was perfused through the circulatory system of the rats post-
euthanasia in order to assay for functional blood vessels. The control group 
demonstrated infiltration of vessels into the mPCL/Col-Hep biomaterial (Figure 
39). mCPL/Col-Hep discs delivering 100 ng VEGF had increased blood 
vessels infiltrating into, as well as around the periphery of the biomaterial 
(Figure 39). Larger vessels were also seen close to the implants in this group 
(Figure 39d). Only mPCL/Col-Hep delivering 10 mM PDCA (Figure 39) and 10 
μM HDZ (Figure 39) showed an onset of vessel infiltration into the 
biomaterials delivering PHi. 
 
 
Figure 37 Explanted mPCL/Col-Hep discs. Blood vessels could be seen around 
the biomaterials, particularly for the biomaterials delivering CPX and HDZ. Red 





5.3.7 Endothelial cell infiltration into implants   
 
Besides studying the infiltration of blood vessels into the mPCL/Col-Hep 
biomaterials, migration of endothelial cells that had yet to form functional 
capillaries were of interest to us as well. Cross-sections of the explants were 
immunostained for the rat endothelial cell antigen-1 (RECA-1), and some of 
the cells that had infiltrated into the biomaterial did appear to be endothelial 
cells (Figure 40a). The number of RECA-1 positive cells were scored by 
Metamorph® software and quantified (Figure 40b). There was an increase in 
the percentage of RECA-1 expressing cells surrounding and within materials 
delivering VEGF, 1 mM PDCA, 0.8 μM and 8 μM CPX and both 10 μM and 




Figure 38 Histological assessment of peri-implantational fibrosis and cell 
infiltration. 10 μm cross-sections were stained with H&E. (a) Fibrous encapsulation 
of the biomaterials was not prominent. 100x magnification, scale bar represents 200 
μm. (b) Cells had completely infiltrated all the mPCL/Col-Hep biomaterials. 200x 
magnification, scale bar represents 100 μm. (c) Vessels were not seen within the 
core of the implants. 400x magnification, scale bar represents 40 μm. An asterisk 




Figure 39 DiI perfusion assay to assess for functional blood vessel infiltration 
into implants. Post-euthanasia, DiI (red) was perfused through the rats circulatory 
system to assay for functional blood vessels. Tissues were cryosectioned to 100 μm 
thickness. Bright field images of the biomaterials were included in the image overlays 
to define the boundary of the implanted discs. Control mPCL/Col-Hep implants show 
some vessel infiltration. mPCL/Col-Hep delivering 100 ng VEGF per disc appeared to 
have an increase of tortuous and larger vessels in the periphery of the biomaterials. 
This DiI assay only detected the appearance of blood vessel infiltration in mPCL/Col-
Hep + PHi discs delivering 10 mM PDCAand 10 μM HDZ. An asterisk denotes 
location of the biomaterial and white arrows highlight vessel infiltration. 100x 




Figure 40 Assessment of endothelial cell infiltration into the implants. (a) 10 
μm cross-sections were immunostained for RECA-1 (red) and counterstained with 
DAPI (blue). There appeared to be endothelial cell infiltration into the implants. An 
asterisk denotes location of the biomaterial, and white dotted lines mark out the 
borders of the implant. 100x magnification. (b) Cell scoring for cells positively 
expressing RECA-1. (i) An image of the control with regions marked out by the 
software according to parameters as positive RECA-1 staining (green). (ii) An image 
of nuclei identified by the software (red), overlapped with regions identified by the 
software as positive for RECA-1 (green). (iii) Nuclei that overlap with RECA-1 
staining are positively scored (green), and nuclei not overlapping with RECA-1 are 
considered negative (red). These two cell types are then quantified to obtain the 
percentage of RECA-1 positive cells per field (c) and the total number of cells per 




The bottleneck of peri-implantational fibrosis in tissue engineering has yet to 
be solved and a balance needs to be found between the bodys natural wound 
repair mechanism and overzealous collagen I deposition. The encapsulation 
of an implant not only impedes the implants original remedial purpose, it can 
further exacerbate the problem. As a proof-of concept to address this issue, 
we have selected three commercially available compounds from the class of 
PHi that was previously screened to demonstrate a reduction of collagen I 
deposition in the Scar-in-a-Jar (Chapter 3) [10]. Besides tackling antifibrosis, a 
potential angiogenic effect of these inhibitors [11] is highly advantageous in 
encouraging assimilation of the implant with the surrounding host tissue. At 
this point, the stability of small chemical compounds is also attractive when 
considering modes of delivery in comparison with labile growth factors, 
enzymes, viral vectors or microRNAs. Several factors were considered when 
developing and testing our biomaterials: 
 
1. Choice of material(s) and pore size 
2. Drug delivery 
3. Support cell attachment, proliferation and infiltration 
a. Antifibrotic properties in vitro 
b. Angiogenic properties in vitro 
4. De novo growth factor reservoir 
5. Efficacy of antifibrotic properties in vivo 
6. Efficacy of angiogenic properties in vivo 
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5.4.1 Choice of material(s) and pore size 
 
Sung et al, 2004, found that using PCL with its slow degradation rate, as a 
scaffold material, resulted in significantly more infiltration of inflammatory and 
endothelial cells compared with poly D, L-lactic-glycolic acid co-polymer 
(PLGA) [218]. Besides improving cell attachent by the inclusion of collagen I 
in the microfiber component, it was previously demonstrated that 
myofibroblasts cultured on collagen secreted more VEGF than on PCL [219]. 
Hence by blending this natural material with a synthetic one, we intend to 
improve inherent angiogenic properties of the material whilst retaining 
mechanical strength.  
 
The mPCL/Col-Hep construct we created to deliver the PHi was also 
developed with pore sizes sufficiently large for vertical cell migration to take 
place. This was achieved by the electrospraying of HeprasilTM simultaneously 
with electrospun mPCL and collagen I microfibers. The hyaluronic acid 
hydrogel created pockets of space between microfibers, thus increasing pore 
sizes within the material and prevented its compaction [214]. 
 
5.4.2 Drug delivery 
 
Rather than administering PHi through multiple localized injections at the 
affected site [220], we chose to deliver the drugs locally via the implanted 
material in two different modes, the hydrogel component (mode 1) or the 
microfiber component (mode 2). A dose-dependent burst release profile was 
obtained for delivery of PHi within the hyaluronic acid hydrogel component 
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(mode 1), whereas a reduced, slow and steady release profile was shown for 
delivery of PHi within the mPCL/Col microfibers (mode 2), and in some cases, 
PHi released may have been below the limits of detection by 
spectrophotometry. It may be advantageous to provide a burst release of 
inhibitors from the material during the first week of implantation when FBR is 
triggered [7] in order to prevent or reduce collagen from encapsulating the 
implant, in addition to giving the PHi a chance to stimulate VEGF production. 
However, if the material completely releases the entire amount of drugs within 
7 to 14 days, then formation of an avascular collagen capsule could still occur. 
Perhaps a combination of both delivery modes might be ideal. Interestingly, 
even with such low amounts of PHi being released via mode 2, there was still 
an increase in VEGF secretion from fibroblasts cultured on the materials 
delivering 1 mM PDCA, 0.8 μM and 8 μM CPX even after 14 days, along with 
a reduction of collagen I secretion. 
 
5.4.3 Support cell attachment, proliferation and infiltration 
 
Depending on the purpose of a material, cell attachment, proliferation and 
infiltration in the material can be vital for integration with the surrounding host 
tissue, and these characteristics were previously demonstrated with 
mPCL/Col-Hep constructs in vitro [214]. We were initially concerned that the 
incorporation of PHi into the mPCL/Col-Hep material would interfere or even 
inhibit cell attachment and proliferation since ECM production is affected. 
However, in vitro cell behaviour on mCPL/Col-Hep delivering PHi was not 
impaired, and cell infiltration into the material was not impeded. 
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5.4.3.1 Antifibrotic property in vitro 
 
There was no clear correlation between the concentrations of the three 
inhibitors and their effect on reducing collagen I secretion. Interestingly, there 
were still inhibitory effects by PHi delivered via mode 2 even though the drugs 
were released in lower amounts compared with mode 1, suggesting that 
localized drug presentation to cells might improve their performance.  Perhaps 
the efficacy of the materials may be more pronounced if this test had been 
carried out in the presence of TGF-1. 
 
5.4.3.2 Angiogenic property in vitro 
 
Besides peri-implantational fibrosis, another major bottleneck in the clinical 
application of tissue engineering to repair metabolically demanding tissues, is 
the absence of a capillary bed connecting the construct to the host blood 
system [9]. Due to their active role in angiogenesis, ECs are a key cell type 
[221]. Hence, it is important to assess EC behaviour on our mPCL/Col-Hep 
materials delivering PHi. A coculture system of IMR-90 fibroblasts and 
HUVECs on the materials was used to demonstrate the absence or presence 
of CLS formed by endothelial cells in response to the materials they were 
cultured on. Positive controls with exogenous VEGF added to the culture 
medium all formed CLS. It was interesting to note that for both modes of PHi 
delivery, formation of CLS did not necessarily correspond with VEGF 
secretion profiles. For mode 1, fibroblasts culture on materials delivering 0.8 
μM and 40 μM CPX showed increased VEGF secretion and formation of CLS, 
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but quantified VEGF for 10 mM PDCA samples and all HDZ samples were not 
significantly increased in comparison with controls, yet HUVECs were able to 
form CLS on these materials. For mode 2, there was increased VEGF 
secretion from fibroblasts culture on 1 mM PDCA and 0.8 μM CPX, and this 
corresponded with CLS formation. However, materials delivering 50 mM 
PDCA did not cause increased VEGF secretion from fibroblasts, yet CLS were 
able to form. From these two data sets, it would seem insufficient if only 
fibroblast VEGF secretion profiles were used to draw a conclusion on potential 
angiogenic performance of the materials. Profiles of other factors contributing 
to angiogenesis such as VEGF receptors, FLT-1, angiopoietin-1 and -2, bFGF 
(FGF-2) and Tie-2 need to be investigated. Thorough in vitro analysis can only 
provide an estimate prediction of what might occur in vivo, and from previous 
investigations, the performance of different PHi and their various 
concentrations in vivo can vary [11]. Hence it is vital that our investigation 
progressed to the next level of testing involving animals, but only when 
materials with suitable potential have been identified. 
 
5.4.4 De novo growth factor reservoir 
 
The idea to deliver VEGF through a material has been proposed earlier [183, 
185, 222-224]. However, stimulating production of endogenous VEGF and 
other angiogenic factors such as bFGF, and angiopoietin 1 for example, and 
storing it for sustained release whilst treating peri-implantational fibrosis is a 
novel idea. Our intention to develop a VEGF reservoir within our material 
stems from evidence that long-term delivery of a single growth factor, VEGF, 
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in appropriate microenvironment amounts can induce the growth of stable 
vessels with normal morphology and function [184].  
 
The rate of growth factor storage is a function of a few factors: 
a. The release rate of PHi 
b. The efficacy of PHi 
c. The number of fibroblasts/cells available to make VEGF/GFs of interest 
d. The amount of heparin available for storage 
 
We demonstrated a dose-dependent storage of exogenous VEGF within the 
mPCL/Col-Hep material, as well as endogenous VEGF produced by 
fibroblasts stimulated by PHi, particularly 8 μM and 40 μM CPX, and 500 μM 
HDZ. This VEGF was then released over a period of 14 days, followed by a 
hyaluronidase digest to completely quantify any remaining VEGF bound by 
heparin in the hyaluronic acid hydrogel. There was a decreasing amount of 
VEGF released over time, with none detected after 14 days. However, 
released VEGF quantified following the hyaluronidase digest was more than 
amounts obtained after 7 and 14 days in some conditions, thus indicating that 
not all VEGF was released rapidly by passive diffusion and remained bound 
within the hydrogel. This can be advantageous as a study by Silva and 
Mooney, 2010, suggested that a high initial dose of VEGF followed by a 




Comparing the study of fibroblasts seeded directly on materials delivering PHi 
versus the VEGF reservoir study, where fibroblasts were cultured in hanging 
inserts separated from the material and stimulated via addition of PHi to the 
culture medium, localized PHi delivery to cells appeared to make a difference.  
Although it can be argued that there was a difference in fibroblast numbers 
involved, 300,000 fibroblasts seeded directly on the material compared with 
8,500 fibroblasts seeded within the inner chamber of the hanging insert. 
However, in the case of PDCA treatment, VEGF storage was not significantly 
increased when fibroblasts were dosed through the culture medium, yet VEGF 
secretion was significantly increased by fibroblasts cultured directly on the 
materials regardless of the mode of delivery. These results may be due to the 
polar nature of PDCA and its difficulty in being transported through the 
cytoplasmic membrane [225], which is why millimolar amounts of PDCA are 
used in comparison with micromolar amounts of CPX and HDZ. Hence, 
increased local concentration around the fibroblasts cultured directly on the 
material may have improved its uptake and thus explain its increase in 
efficacy.  
 
HeprasilTM  has 0.3% (w/w) of heparin cross-linked into the hyaluronic acid 
hydrogel, and it is natural to assume that by increasing the heparin content, 
the storage capacity of our material will be improved as well. While this makes 
common sense, it is important to note however, that increasing the amount of 
heparin was previously demonstrated to reduce growth factor release [226], 
which would be undesirable if our intention was to deliver growth factors with 
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a burst release. Since this is not the case though, heparin content may be an 
interesting factor for further optimization. On the other hand, this growth factor 
release study was performed cell free, hence it is possible that our VEGF 
release profile might differ if cells, particularly endothelial cells came into 
direct contact with the material. The ability to store VEGF within the material 
may not only provide a localized source for such cells even in picogram 
amounts, but may also provide a concentration gradient of VEGF towards the 
implant thus directing vessel growth.  
 
5.4.5 Preliminary in vivo testing 
 
The rat renal pouch model was used for a preliminary assessment of the 
angiogenic and antifibrotic potential of our mPCL/Col-Hep constructs 
delivering PHi. This animal model is currently used to provide graft 
prevascularization prior to cardiac implantation, and was previously 
demonstrated as an easy and efficient way to supply tissue engineered 
constructs with autologous blood vessels [216]. Our materials were also 
implanted cell-free, with the intention to recruit and modulate the hosts cells in 
the tissue engineering process. Chen et al, 2008, previously demonstrated 
that implantation of electrospun mPCL/Col constructs without pre-seeding of 
autologous cells in the corpus cavernosum resulted in a foreign body reaction 
and formation of a collagen capsule around the material [38], which we intend 
to circumvent with the inclusion of PHi.  Delivery of PHi via the hyaluronic acid 
hydrogel component (mode 1) was selected for the first stage of in vivo 
testing. The rationale being that a burst release of PHi may be optimal in 
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preventing excessive collagen I deposition around the implant, together with 
increased VEGF production from fibroblasts for storage in the material thus 
creating a VEGF gradient. The two lowest concentrations of each PHi were 
selected for in vivo testing based on in vitro data and the need to limit the 
number of animals used in this preliminary trial.  
 
5.4.5.1 Efficacy of antifibrotic properties in vivo 
 
Previous investigations have determined that materials with lower porosity 
have an increased likelihood to induce dense fibrous capsule formation [227], 
and randomly-oriented electrospun PCL nanofibers not only show limited 
ability for cell infiltration [228-230], but also incite a strong foreign body 
response [230]. However, in our study, in vivo cellular infiltration into 
mPCL/Col-Hep constructs was observed with minimal foreign body response, 
even in controls not containing any PHi. This may be attributed to the inherent 
physical characteristics of the material itself, and the presence of suitable 
pore size [231, 232] may trump orientation of the fibers and contribute to an 
intrinsic antifibrotic effect. Perhaps implantation time should be increased from 
one week to four weeks in order to understand the longer-term consequences 
of our implanted materials, and because the acute and chronic inflammatory 







5.4.5.2 Efficacy of angiogenic properties in vivo 
 
Macroscopic inspection found that explants of mPCL/Col-Hep delivering CPX 
appeared to have increased vessels in the periphery of tissues surrounding 
the material, and materials with HDZ had an increase of finer vessels in the 
adjacent tissues. Endothelial cell proliferation occurs early in the angiogenic 
process before tube formation, pericyte recruitment or vessel stabilization 
[234]. Addition of VEGF, PDCA, CPX or HDZ into mPCL/Col-Hep appeared to 
cause an increase in the number of endothelial cells in the periphery of and 
within the implanted materials in comparison with controls, thus indicating 
potential for improved angiogenesis. Delivery of VEGF via the mPCL/Col-Hep 
material appeared to not only increase the number of blood vessels in the 
periphery of the implant, but vessels diameters as well. There also seemed to 
be more blood vessel infiltration into the material compared with controls and 
materials delivering PHi, although 10 mM PDCA and 10 μM HDZ did show 
infiltration.  This may be explained by the lag in VEGF production by cells in 
response to PHi treatment, in contrast to materials directly delivering VEGF. In 
vitro analysis demonstrated that day 2 of culture did not produce an increase 
in VEGF secretion by fibroblasts, and the maximal VEGF 
secretion/accumulation was at day 7, although daily time points were not 
assessed and this assay does not take VEGF degradation into account. Also, 
endogenous VEGF storage within the material in response to certain PHi 
appeared to eventually equilibrate at levels similar to storage of high doses of 
exogenous VEGF. Perhaps the relatively short time point of 7 days for this 
 135 
preliminary in vivo study was insufficient to truly assess the angiogenic 




This work describes the design and development of a novel antifibrotic and 
angiogenic material to prevent peri-implantational fibrosis. We took advantage 
of the dual antifibrotic and angiogenic benefits of PHi, and designed a material 
to fulfill specific criteria in terms of drug delivery, tissue compatibility, and 
storing growth factors to prolong angiogenic signalling. Although a short 
implantation period was used, acellular rat renal pouch implants including 
controls, had minimal fibrosis and showed potential for vascularization. With 
further optimization of drug delivery, it may be possible to enhance intrinsic 











6.1 Conclusions  
 
As of this writing, it has not yet been possible to create a material that 
circumvents the ability of the mammalian immune systems to distinguish 
foreign from self, and we do not claim to have found the solution yet either. A 
foreign body response often results in the sequestration of the implant from 
the body within an avascular collagen capsule. Hence to take a step in the 
direction of preventing peri-implantational fibrosis, we have established a 
workflow combining a screening assay for potential antifibrotic compounds, 
with the design and development of materials incorporating selected 
compounds.  
 
In order to overcome the first roadblock of antifibrotic compound identification 
in vitro, we developed a screening assay nicknamed the Scar-in-a-Jar. This 
system implemented the biophysical phenomenon of macromolecular 
crowding to apply the excluded-volume effect in cell culture. Addition of 
macromolecules enhanced procollagen C-propeptide cleavage, collagen 
supramolecular assembly and collagen cross-linking, thus increasing the 
amount of collagen deposited on the cell layer within a shorter timeframe 
compared with uncrowded controls, and superior to fibroplasia models 
adopted by industry. Two modes of high-content throughput assessment were 
created to identify potential antifibrotic compounds. The rapid and accelerated 
mode presents different rates, morphologies and composition of deposited 
ECM to provide options of pathophysiologically relevant in vitro environments 
for the evaluation of antifibrotic lead compounds interfering with various key 
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points of the collagen biosynthesis pathway, thus affecting the overall amount 
of deposited collagen normalized to cell numbers. The in situ nature of this 
assay reduces sample manipulation, thus minimizing sample variance and 
providing convenience.  
 
The Scar-in-a-Jar was able to efficiently discern a reduction of collagen I 
caused by inhibitors targeting the collagen biosynthesis pathway from the 
epigenetic to extracellular level, including procollagen C-proteinase inhibitors. 
However, the collagen cross-linking inhibitor, BAPN, appeared to be 
ineffective in our system. With the reduction of cross-links, collagen would 
become more susceptible to matrix metalloproteinase degradation (i.e. 
collagen turn over) and the failure to reduce overall deposited collagen I may 
perhaps be due to the short time frame in which screening took place. 
 
To develop an antifibrotic material, several candidate inhibitors were screened 
and considered. Small chemical compounds were favoured over microRNAs 
and enzymes because they are comparatively robust and more likely to 
withstand the materials fabrication process. Prolyl-4-hydroxylase inhibitors 
such as PDCA, CPX and HDZ were particularly attractive due to their 
additional angiogenic potential, and CPX and HDZ are approved by the FDA 
as a topical antifungal agent and an antihypertensive drug, respectively, and 
this would make translation into clinical trials easier. 
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In order to improve integration of our cell-free implant with host tissue, several 
factors were considered in the materials design. A mPCL/Col-Hep composite 
material was tailored to have intrinsic antifibrotic and angiogenic properties 
based on the materials used and sufficiently large pore sizes for cell 
infiltration. Two modes were developed for localized delivery of PHi, within the 
hyaluronic acid hydrogel (burst release, mode 1) and the mPCL/Col 
microfibers (sustained release, mode 2). Incorporation of the drugs did not 
interfere with cell attachment and proliferation. The delivered PHi remained 
bioactive by reducing collagen I and increasing VEGF secretion by fibroblasts, 
as well as inducing endothelial cells to form CLS in a coculture system with 
fibroblasts. The HeprasilTM hydrogel served as a de novo growth factor 
reservoir, and demonstrated the capability of being loaded with VEGF 
produced by fibroblasts in response to PHi stimulation, followed by sustained 
release of the stored VEGF as a proof-of-concept.  
 
A rat renal pouch model was selected for our preliminary in vivo study, and 
mPCL/Col-Hep delivering PHi via the hydrogel component (mode 1) 
demonstrated minimal fibrosis for all implants, with initial stages of 
vascularization at the peripheries of the control, VEGF, 10 mM PDCA and 10 
μM HDZ biomaterial implants. Delivery of VEGF, CPX and HDZ also 
increased the proportion of endothelial cells within and around the periphery 
of the implant compared with controls. An extended implantation period up to 
28 days may be better to assess the true antifibrotic and angiogenic potential 
of the materials. 
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Unstopping the bottleneck of peri-implantational fibrosis in tissue engineering 
still eludes us, but streamlining the process may hasten the solution to this 





6.2 Future work 
The pleiotropic effects of macromolecular crowding are constantly being 
investigated, and a greater understanding of its effects in cell culture is slowly 
being revealed. 
 
We need to refine the design of our materials to improve on concentrations 
and modes of drug delivery, and a more in-depth characterization of the 
drugs effect on angiogenic factors is required. Investigations into improving 
the capacity of the growth factor reservoir within the material, by increasing 
heparin content are also being considered. 
 
The rat renal pouch model [216] was designed for prevascularization of 
constructs prior to cardiac implantation because prevascularization has been 
shown to improve therapeutic outcome [235]. This animal model was selected 
for our preliminary in vivo study, because our material is designed with the 
future intention to develop a cardiac patch. Only after further optimization and 
if promising results are obtained in the next round of testing, will we advance 
to surgically repair the hearts left ventricle after a myocardial infarction 
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A.1 Standard curves for PHi drug release measurement 
 
 
Figure A 1 Standard curves of PHi measured by spectophotometry. (a) PDCA 
was measured at an absorbance of 276 nm from a range of 0.01 mM to 1 mM 
(0.37 μg to 27.75 μg) PDCA. (b) CPX was measured at an absorbance of 305 
nm from a range of 0.1 μM to 25 μM (5.36 ng to 2144 ng) CPX. (c) HDZ was 
measured at an absorbance of 304 nm from a range of 1μM to 500 μM (40 ng 
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